Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Tuberculosis

  Free Subscription


Articles published in Int J Tuberc Lung Dis

Retrieve available abstracts of 458 articles:
HTML format



Single Articles


    March 2024
  1. OTA M, Hirao S, Uchimura K
    Lower TB notification rates in later life in the same birth cohort, Japan, 1950-2020.
    Int J Tuberc Lung Dis. 2024;28:157-159.
    PubMed    


  2. PONTALI E, Akkerman OW, Zenner D, Migliori GB, et al
    Post-TB lung disease: keep going beyond TB!
    Int J Tuberc Lung Dis. 2024;28:113-114.
    PubMed    


  3. THEKKUR P, Thiagesan R, Nair D, Karunakaran N, et al
    Using timeliness metrics for household contact tracing and TB preventive therapy in the private sector, India.
    Int J Tuberc Lung Dis. 2024;28:122-139.
    PubMed     Abstract available


  4. SOUSA S, Santos S, Alves CM, Goncalves G, et al
    Impact of annual TB screening on stone quarry workers in high-incidence Portuguese municipalities.
    Int J Tuberc Lung Dis. 2024;28:136-141.
    PubMed     Abstract available


  5. THOMSON H, Baines N, Huisamen T, Koegelenberg CFN, et al
    A new understanding of clinical patterns in post-TB lung disease.
    Int J Tuberc Lung Dis. 2024;28:115-121.
    PubMed     Abstract available


  6. LEVER S, Akkerman OW, Dekkers BGJ
    Pancreatitis delays the absorption of first-line anti-TB drugs.
    Int J Tuberc Lung Dis. 2024;28:163-165.
    PubMed    


  7. YAMKOVOY K, Self JL, Jenkins HE, Horsburgh CR, et al
    Patterns of TB transmission in the United States, 2011-2017.
    Int J Tuberc Lung Dis. 2024;28:154-156.
    PubMed    


  8. REZAEE M, Azizi N, Danaei B, Davari A, et al
    TB and interstitial lung disease: a systematic review and meta-analysis.
    Int J Tuberc Lung Dis. 2024;28:130-135.
    PubMed     Abstract available


  9. RUDOLF F, Abate E, Moges B, Gomes VF, et al
    A structured 2-week follow-up visit in the cascade of care for TB increases case detection.
    Int J Tuberc Lung Dis. 2024;28:148-153.
    PubMed     Abstract available


  10. LEAVITT SV, Rodriguez CA, Bouton TC, Horsburgh CR, et al
    Outcomes for people with TB by disease severity at presentation.
    Int J Tuberc Lung Dis. 2024;28:142-147.
    PubMed     Abstract available


    February 2024
  11. SILVA DR, Santos AP, Visca D, Bombarda S, et al
    The potential for vaccines to aid the treatment of post-TB lung disease.
    Int J Tuberc Lung Dis. 2024;28:44-45.
    PubMed    


  12. LONG R, Heffernan C, Lau A
    Emphasis on post-TB lung disease and other sequelae of TB is good but a public health approach to TB is morally ambitious???
    Int J Tuberc Lung Dis. 2024;28:1-3.
    PubMed    


  13. FEKADU G, Wang Y, You JHS
    Cost-effectiveness of pretomanid-based regimen for highly drugresistant TB in a low-burden setting.
    Int J Tuberc Lung Dis. 2024;28:12-17.
    PubMed     Abstract available


  14. TURNER RD, Birring SS, Bothamley GH
    Measuring cough-related quality of life and cough frequency in pulmonary TB.
    Int J Tuberc Lung Dis. 2024;28:25-31.
    PubMed     Abstract available


  15. SHIN JE, Jeon D, Mok J, Yim JJ, et al
    Compliance with new drug use and the effect of discrepant drug susceptibility testing on MDR/RR-TB treatment.
    Int J Tuberc Lung Dis. 2024;28:18-24.
    PubMed     Abstract available


  16. DOLEZALOVA K, Kika V, Wallenfels J
    Increasing incidence of TB in a low burden TB country due to migration from Ukraine.
    Int J Tuberc Lung Dis. 2024;28:39-40.
    PubMed    


  17. NIGHTINGALE ES, Feasey HRA, Khundi M, Soko RN, et al
    Community-level variation in TB testing history in Blantyre, Malawi.
    Int J Tuberc Lung Dis. 2024;28:32-38.
    PubMed     Abstract available


    January 2024
  18. YILDIRIM K, Bozkurt S, Basibuyuk HH, Coban AY, et al
    Anti-tuberculosis activity of morusin: a promising flavonoid from white mulberry.
    Int J Tuberc Lung Dis. 2024;28:37-41.
    PubMed     Abstract available


  19. KUMAR SR, Hissar SS, Ramesh PM, Shanmugam M, et al
    Ethambutol-induced optic neuropathy: should we mandate ophthalmic examination in TB treatment?
    Int J Tuberc Lung Dis. 2024;28:51-53.
    PubMed    


  20. SURIE D, Sathyanarayanan MK, Lavanya J, Smith JP, et al
    Long-term follow-up of persons diagnosed with multidrug-resistant TB in Chennai, India, 2013-2020.
    Int J Tuberc Lung Dis. 2024;28:54-56.
    PubMed    


  21. RICCARDI N, Antonello RM, Besozzi G, Tadolini M, et al
    Ten common myths about drug-susceptible TB.
    Int J Tuberc Lung Dis. 2024;28:61-64.
    PubMed    


  22. DU Y, Gu J, Yang Y, Chen Y, et al
    Efficacy and safety of bicyclol for treating patients with antituberculosis drug-induced liver injury.
    Int J Tuberc Lung Dis. 2024;28:6-12.
    PubMed     Abstract available


  23. BEELER ASAY GR, Woodruff R, Sanderson DM, Fisher CF, et al
    Cost-effectiveness of expanded latent TB infection testing and treatment: Lynn City, Massachusetts, USA.
    Int J Tuberc Lung Dis. 2024;28:21-28.
    PubMed     Abstract available


  24. SCHILDKRAUT JA, Sloan D, Boeree MJ
    If you want to go far, go together: standardisation and data sharing in TB drug development.
    Int J Tuberc Lung Dis. 2024;28:3-5.
    PubMed    


  25. HOUBEN RMGJ, McCaffrey T, Tiemersma EW, Khan PY, et al
    Estimating TB survival - mind the immortal-time gap.
    Int J Tuberc Lung Dis. 2024;28:65-66.
    PubMed    


  26. YUAN S, Cui Y, Shang Y, Su F, et al
    Prevalence, temporal trends and risk factors of drug-resistant TB in Zibo, China, 2018-2021.
    Int J Tuberc Lung Dis. 2024;28:57-58.
    PubMed    


  27. GEIGER K, Patil A, Bergman A, Budhathoki C, et al
    Exploring HIV disease indicators at MDR-TB treatment initiation in South Africa.
    Int J Tuberc Lung Dis. 2024;28:42-50.
    PubMed     Abstract available


  28. OLIVEIRA DA SILVA B, Salindri AD, Goncalves TO, Cunha EAT, et al
    The impact of sputum quality on Xpert positivity in active case-finding for TB.
    Int J Tuberc Lung Dis. 2024;28:29-36.
    PubMed     Abstract available


  29. TYUFEKCHIEVA M, Varleva T
    Monitoring TB infection in contact cases: the impact of the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2024;28:59-60.
    PubMed    


    December 2023
  30. YANG H, Antwi S, Maranchick N, Dompreh A, et al
    Effect of HIV infection on plasma exposure to first-line TB drugs and target attainment in children.
    Int J Tuberc Lung Dis. 2023;27:931-937.
    PubMed     Abstract available


  31. MAKEK MJ, Trauer JM, Blackbourn HD
    Literature Highlights.
    Int J Tuberc Lung Dis. 2023;27:882-884.
    PubMed     Abstract available


  32. ARAUJO-PEREIRA M, Andrade BB
    Atorvastatin to reduce bacillary load and attenuate lung damage in TB patients.
    Int J Tuberc Lung Dis. 2023;27:880-881.
    PubMed    


  33. COMMIESIE E, Stijnberg D, van den Boogaard J, Gopie F, et al
    Challenges and opportunities for TB elimination in Suriname.
    Int J Tuberc Lung Dis. 2023;27:946-948.
    PubMed    


  34. RAGHEB SM, White JB, Jarand J, Fisher DA, et al
    Assessing patient satisfaction with video-supported therapy for drug-susceptible TB treatment.
    Int J Tuberc Lung Dis. 2023;27:938-940.
    PubMed    


  35. CHUNG C, Jo KW, Shim TS
    Treatment outcome, recurrence and safety of multidrug-resistant TB treated with low-dose linezolid.
    Int J Tuberc Lung Dis. 2023;27:918-924.
    PubMed     Abstract available


  36. DU CROS P, Greig J, Alffenaar JC, Cross GB, et al
    Standards for clinical trials for treating TB.
    Int J Tuberc Lung Dis. 2023;27:885-898.
    PubMed     Abstract available


  37. ADEWOLE OO, Omotoso BA, Ogunsina M, Aminu A, et al
    Atorvastatin improves sputum conversion and chest X-ray severity score.
    Int J Tuberc Lung Dis. 2023;27:912-917.
    PubMed     Abstract available


  38. QUINCER EM, Lyland A, Onyango D, LaCourse SM, et al
    The effect of antenatal isoniazid preventive therapy on birth outcomes in Western Kenya.
    Int J Tuberc Lung Dis. 2023;27:906-911.
    PubMed     Abstract available


  39. NETO ERD, Matos TS, Ferreira ACF, Bezerra-Santos M, et al
    The impact of COVID-19 on TB care in Brazil.
    Int J Tuberc Lung Dis. 2023;27:941-943.
    PubMed    


  40. MENDOZA-TICONA A, Mitnick CD, Obregon G, Alarcon V, et al
    Screening with GenoType((R)) MTBDRplus shortens the time to MDR-TB treatment initiation but does not change outcomes.
    Int J Tuberc Lung Dis. 2023;27:949-951.
    PubMed    


  41. KIBIRIGE D, Andia-Biraro I, Olum R, Adakun S, et al
    Metabolic characterisation of adult Ugandan patients with TB and diabetes mellitus comorbidity.
    Int J Tuberc Lung Dis. 2023;27:944-945.
    PubMed    


    November 2023
  42. EDWARDS S, Humbert T, Berdzuli N, Azzopardi-Muscat N, et al
    Tackling TB in Europe: treatment gaps and deteriorating treatment availability is undermining progress.
    Int J Tuberc Lung Dis. 2023;27:793-796.
    PubMed    


  43. MARGINEANU I, Butnaru T, Gafar F, Baiceanu D, et al
    TB therapeutic drug monitoring - analysis of opportunities in Romania and Ukraine.
    Int J Tuberc Lung Dis. 2023;27:816-821.
    PubMed     Abstract available


  44. KATRAK S, Wang R, Barry P
    Costs of treating multidrug-resistant TB in California in 2022.
    Int J Tuberc Lung Dis. 2023;27:864-866.
    PubMed    


  45. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
    A novel home-based method for preparing suspensions of anti-TB drugs.
    Int J Tuberc Lung Dis. 2023;27:810-815.
    PubMed     Abstract available


  46. INBARAJ LR, Rade K, Selvaraju S, Rao R, et al
    Mortality estimates of central nervous system TB in India.
    Int J Tuberc Lung Dis. 2023;27:876-877.
    PubMed    


  47. FRITSCHI N, Vaezipour N, Buettcher M, Portevin D, et al
    Ratios from full blood count as markers for TB diagnosis, treatment, prognosis: a systematic review.
    Int J Tuberc Lung Dis. 2023;27:822-832.
    PubMed     Abstract available


    October 2023
  48. ANDREWS F, Welch S, Scandrett K, Kaur H, et al
    Outcomes of TB contact tracing and predictors of success: a 10-year retrospective cohort analysis in Birmingham, UK.
    Int J Tuberc Lung Dis. 2023;27:766-771.
    PubMed     Abstract available


  49. TRAUER JM, Tiberi S, Graham SM, Blackbourn HD, et al
    Literature Highlights.
    Int J Tuberc Lung Dis. 2023;27:721-723.
    PubMed     Abstract available


  50. NELSON KN, Shah NS, Cranmer LM, Vasudevan L, et al
    An effective vaccine is only the first step: the need to create and sustain demand for TB vaccines.
    Int J Tuberc Lung Dis. 2023;27:718-720.
    PubMed    


  51. PUMA D, Geadas C, Calderon RI, Yuen CM, et al
    Active case-finding for TB among incarcerated women in Peru.
    Int J Tuberc Lung Dis. 2023;27:784-786.
    PubMed    


  52. AKKERMAN OW, Dijkwel RDC, Kerstjens HAM, van der Werf TS, et al
    Isoniazid and rifampicin exposure during treatment in drug-susceptible TB.
    Int J Tuberc Lung Dis. 2023;27:772-777.
    PubMed     Abstract available


  53. CHIANG SS, Zeng C, Roman-Sinche B, Altamirano E, et al
    Adaptation and validation of a TB stigma scale for adolescents in Lima, Peru.
    Int J Tuberc Lung Dis. 2023;27:754-760.
    PubMed     Abstract available


  54. KIM JY, Koo B, Lim SY, Cha HH, et al
    A non-invasive, sensitive assay for active TB: combined cell-free DNA detection and FluoroSpot assays.
    Int J Tuberc Lung Dis. 2023;27:790-792.
    PubMed    


  55. REKART ML, Aung A, Cullip T, Mulanda W, et al
    Household drug-resistant TB contact tracing in Tajikistan.
    Int J Tuberc Lung Dis. 2023;27:748-753.
    PubMed     Abstract available


  56. RAJAVARDHANA T, Koushik MR, Jayakumar C, Ramalingam P, et al
    Adherence to treatment on a daily-dose regimen for TB.
    Int J Tuberc Lung Dis. 2023;27:778-780.
    PubMed    


  57. SINGH UB, Ray Y, Kanswal S, Sharma HP, et al
    Low rifampicin levels in plasma associated with a poor clinical response in patients with abdominal TB.
    Int J Tuberc Lung Dis. 2023;27:787-789.
    PubMed    


  58. FRAZIER C, Nabity SA, Flood J
    Incidence of TB disease among persons who use drugs in California.
    Int J Tuberc Lung Dis. 2023;27:781-783.
    PubMed    


  59. RAJENDRAN P, Saini S, Kumar N, Vashistha H, et al
    Establishing proof of concept for utility of Trueprep((R))-extracted DNA in line-probe assay testing.
    Int J Tuberc Lung Dis. 2023;27:742-747.
    PubMed     Abstract available


    September 2023
  60. MACHAVARIANI E, Nonyane BAS, Lebina L, Mmolawa L, et al
    Perceived stigma among people with TB and household contacts.
    Int J Tuberc Lung Dis. 2023;27:675-681.
    PubMed     Abstract available


  61. VILJOEN L, Acaba J, Agbassi YJP, Beko B, et al
    Community perspective on child-friendly medications for drug-resistant TB: importance, priorities and advocacy.
    Int J Tuberc Lung Dis. 2023;27:655-657.
    PubMed    


  62. RODRIGUEZ CA, Leavitt SV, Bouton TC, Horsburgh CR, et al
    Survival of people with untreated TB: effects of time, geography and setting.
    Int J Tuberc Lung Dis. 2023;27:694-702.
    PubMed     Abstract available


  63. BECKER GL, Amuge P, Ssebunya R, Motevalli M, et al
    Predictors of mortality in Ugandan children with TB, 2016-2021.
    Int J Tuberc Lung Dis. 2023;27:668-674.
    PubMed     Abstract available


  64. DO NASCIMENTO DR, Serpa SF, Bezerra-Santos M, do Carmo RF, et al
    The impact of the COVID-19 pandemic on TB diagnosis in the Brazilian prison population, 2020-2021.
    Int J Tuberc Lung Dis. 2023;27:688-693.
    PubMed     Abstract available


  65. GALEA JT, Chu AL, Sweetland AC, Jimenez J, et al
    Latent TB and depressive symptoms in household contacts of persons with active TB.
    Int J Tuberc Lung Dis. 2023;27:682-687.
    PubMed     Abstract available


    August 2023
  66. SILVA DR, Munoz-Torrico M, Fernandes GR, Narvaez-Diaz L, et al
    Isoniazid-resistant TB: treatment outcomes and impact of regimens with fluoroquinolones.
    Int J Tuberc Lung Dis. 2023;27:638-640.
    PubMed    


  67. AHMED S, Lotia-Farrukh I, Khan PY, Adnan S, et al
    High prevalence of multidrug-resistant TB among household contacts in a high burden setting.
    Int J Tuberc Lung Dis. 2023;27:646-648.
    PubMed    


  68. CHIANG SS, Graham SM, Schaaf HS, Marais BJ, et al
    Clinical standards for drug-susceptible TB in children and adolescents.
    Int J Tuberc Lung Dis. 2023;27:584-598.
    PubMed     Abstract available


  69. MAKEK MJ, Amorim GGC, Ragonnet R, Blackbourn HD, et al
    Literature Highlights.
    Int J Tuberc Lung Dis. 2023;27:581-583.
    PubMed     Abstract available


  70. ACUNA-VILLAORDUNA C, Jacobson KR, Horsburgh CR, Canning M, et al
    Initial experience with BPaL-based regimens to treat multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:649-650.
    PubMed    


  71. HACKER B, Breuer C, Priwitzer M, Otto-Knapp R, et al
    TB screening of Ukrainian refugees in Germany.
    Int J Tuberc Lung Dis. 2023;27:641-642.
    PubMed    


  72. HONGPRASIT P, Sonthisombat P
    Assessment of TB treatment adherence using computer-assisted self-interviewing.
    Int J Tuberc Lung Dis. 2023;27:626-631.
    PubMed     Abstract available


  73. RIKHOTSO MC, Ledwaba SE, Ngandu JK, Mavumengwana V, et al
    Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs.
    Int J Tuberc Lung Dis. 2023;27:599-605.
    PubMed     Abstract available


  74. MARITZ ER, Montepiedra G, Mitchell CD, Madhi SA, et al
    Predictors of TB disease in HIV-exposed children from Southern Africa.
    Int J Tuberc Lung Dis. 2023;27:619-625.
    PubMed     Abstract available


  75. CHIBOLELA M, de Haas P, Klinkenberg E, Kosloff B, et al
    Use of stool swabs in molecular transport media increases access to Xpert Ultra testing for TB in children.
    Int J Tuberc Lung Dis. 2023;27:612-618.
    PubMed     Abstract available


  76. HABIB SS, Uzair M, Dhanwani A, Sohail K, et al
    A model for integrating social protection measures with TB control in Pakistan.
    Int J Tuberc Lung Dis. 2023;27:651-652.
    PubMed    


  77. RACHOW A, Ivanova O, Bakuli A, Khosa C, et al
    Performance of spirometry assessment at TB diagnosis.
    Int J Tuberc Lung Dis. 2023;27:850-857.
    PubMed     Abstract available


  78. SALERNO MM, Burzynski J, Mangan JM, Hill A, et al
    Adverse events among persons with TB using in-person vs. electronic directly observed therapy.
    Int J Tuberc Lung Dis. 2023;27:833-840.
    PubMed     Abstract available


  79. OWOLABI OA, Sillah AK, Loum I, Touray A, et al
    Factors associated with presenting to private sector care providers at the onset of TB symptoms.
    Int J Tuberc Lung Dis. 2023;27:867-868.
    PubMed    


  80. SILVESTRE CR, Cavaco M, Afonso R, Alves S, et al
    TB infection in healthcare workers - the reality of a Portuguese hospital.
    Int J Tuberc Lung Dis. 2023;27:874-875.
    PubMed    


  81. CHO MM, Kim HW, Kim JS, Min J, et al
    TB in ageing populations: lessons from Japan and Korea.
    Int J Tuberc Lung Dis. 2023;27:869-871.
    PubMed    


    July 2023
  82. NUR N, Sharif AB, Mitra DK
    Stress resilience in patients with drug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:551-556.
    PubMed     Abstract available


  83. OKOYA F, Huang CC, Zhang Z, Lecca L, et al
    Culture-negative TB: clinical characteristics, risk factors and treatment outcomes.
    Int J Tuberc Lung Dis. 2023;27:557-563.
    PubMed     Abstract available


  84. ESCALANTE P, Vadiyala MR, Pathakumari B, Marty PK, et al
    New diagnostics for the spectrum of asymptomatic TB: from infection to subclinical disease.
    Int J Tuberc Lung Dis. 2023;27:499-505.
    PubMed     Abstract available


  85. STRAUSS M, Wademan DT, Mcinziba A, Hoddinott G, et al
    TB preventive therapy preferences among children and adolescents.
    Int J Tuberc Lung Dis. 2023;27:520-529.
    PubMed     Abstract available


  86. HARRIES AD, Lin Y, Thekkur P, Nair D, et al
    Why TB programmes should assess for comorbidities, determinants and disability at the start and end of TB treatment.
    Int J Tuberc Lung Dis. 2023;27:495-498.
    PubMed    


  87. GLOGOWSKA A, Przybylski G, Bukowski J, Dolska E, et al
    TB and COVID-19 co-infection in a pulmonology hospital.
    Int J Tuberc Lung Dis. 2023;27:574-576.
    PubMed    


  88. FERRARESE M, Antonello RM, Torri S, Saderi L, et al
    Extrapulmonary TB: a 30-year observational study of an Italian cohort.
    Int J Tuberc Lung Dis. 2023;27:564-566.
    PubMed    


  89. WADEMAN DT, Viljoen L, Jacobs S, Meyerson K, et al
    Children s priorities to improve the acceptability of MDR-TB treatment: qualitative data from South Africa.
    Int J Tuberc Lung Dis. 2023;27:543-550.
    PubMed     Abstract available


  90. SINGH KP, Carvalho ACC, Centis R, D Ambrosio L, et al
    Clinical standards for the management of adverse effects during treatment for TB.
    Int J Tuberc Lung Dis. 2023;27:506-519.
    PubMed     Abstract available


  91. MARQUES J, Rocha JV, Soares P, Leite A, et al
    The effect of TB patient delay on loss to follow-up in Portugal.
    Int J Tuberc Lung Dis. 2023;27:537-542.
    PubMed     Abstract available


  92. CENTENO HURTADO KT, Garcia Bohorquez DF, Ruiz Gonzalez CE, Masias Leon Y, et al
    The burden of chronic obstructive pulmonary disease among hospitalised women in a developing country.
    Int J Tuberc Lung Dis. 2023;27:530-536.
    PubMed     Abstract available


  93. VENGURLEKAR D, Walker C, Mahajan R, Dalal A, et al
    Linezolid resistance in patients with drug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:567-569.
    PubMed    


  94. ZUREIGAT H, Alhusban M, Nawaiseh M, Alomari L, et al
    Steps towards TB elimination in Jordan.
    Int J Tuberc Lung Dis. 2023;27:576-577.
    PubMed    


    June 2023
  95. DE VRIES G, Akkerman O, Boeree M, van Hest R, et al
    Diagnosis, treatment and transmission of rifampicin-resistant TB in the Netherlands, 2010-2019.
    Int J Tuberc Lung Dis. 2023;27:471-477.
    PubMed     Abstract available


  96. MALHOTRA A, Mukiibi J, Kitonsa PJ, Nalutaaya A, et al
    Higher yield using an event-based vs. door-to-door approach for active case-finding for TB.
    Int J Tuberc Lung Dis. 2023;27:484-486.
    PubMed    


  97. MAKEK MJ, Tiberi S, Felker I, Amorim GGC, et al
    Literature Highlights.
    Int J Tuberc Lung Dis. 2023;27:429-431.
    PubMed     Abstract available


  98. NI N, Wang N, Veronese V, Wang MZ, et al
    Current status and future prospects of TB digital treatment adherence technology use in China.
    Int J Tuberc Lung Dis. 2023;27:438-443.
    PubMed     Abstract available


  99. KIM SH, Yoo JY, Cho HS, Kim SR, et al
    Clinical and imaging features of drug-susceptible and multidrug-resistant TB in Korean adults.
    Int J Tuberc Lung Dis. 2023;27:487-489.
    PubMed    


  100. LOUIE JK, Keh C, Agraz-Lara R, Phillips A, et al
    Highlighting the characteristics of TB disease in older people.
    Int J Tuberc Lung Dis. 2023;27:478-480.
    PubMed    


  101. SUNG J, Musinguzi A, Kadota JL, Baik Y, et al
    Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda.
    Int J Tuberc Lung Dis. 2023;27:458-464.
    PubMed     Abstract available


  102. OESER C, Rangaka MX, Abubakar I
    Digital approaches to reducing TB treatment loss to follow-up.
    Int J Tuberc Lung Dis. 2023;27:432-437.
    PubMed     Abstract available


  103. RICH ML, Khan U, Zeng C, LaHood A, et al
    Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications.
    Int J Tuberc Lung Dis. 2023;27:451-457.
    PubMed     Abstract available


  104. MYERS B, Carney T, Rooney J, Malatesta S, et al
    Smoked drug use in patients with TB is associated with higher bacterial burden.
    Int J Tuberc Lung Dis. 2023;27:444-450.
    PubMed     Abstract available


  105. OTAALO B, Cevik M, Mwebesa E, Nabisere-Arinaitwe R, et al
    Prevalence of COVID-19 infection in TB clinics in Kampala, Uganda.
    Int J Tuberc Lung Dis. 2023;27:481-483.
    PubMed    


    May 2023
  106. GUNTHER G, Guglielmetti L, Leu C, van Leth F, et al
    Relative cost of multidrug-resistant TB medicines in Europe.
    Int J Tuberc Lung Dis. 2023;27:341-344.
    PubMed    


  107. KWARA A, Yang H, Martyn-Dickens C, Enimil A, et al
    Adequacy of WHO weight-band dosing and fixed-dose combinations for the treatment of TB in children.
    Int J Tuberc Lung Dis. 2023;27:401-407.
    PubMed     Abstract available


  108. GIRIDHARAN P, Devaleenal B, Thiruvengadam K, Kaleeswari M, et al
    A novel method for contact tracing for TB at household and community level.
    Int J Tuberc Lung Dis. 2023;27:414-415.
    PubMed    


  109. SADERI L, Cabibbe AM, Puci M, Di Lorenzo B, et al
    A systematic review of the costs of diagnosis for multidrug-resistant/extensively drug-resistant TB in different settings.
    Int J Tuberc Lung Dis. 2023;27:348-356.
    PubMed     Abstract available


  110. GERIC C, Qin ZZ, Denkinger CM, Kik SV, et al
    The rise of artificial intelligence reading of chest X-rays for enhanced TB diagnosis and elimination.
    Int J Tuberc Lung Dis. 2023;27:367-372.
    PubMed     Abstract available


  111. FAJER EB, Costa FD, Pelissari DM, Diaz Quijano FA, et al
    Use of rapid molecular TB diagnostics for incarcerated people in Brazil.
    Int J Tuberc Lung Dis. 2023;27:416-418.
    PubMed    


  112. KASWASWA K, Mlauzi L, Mpunga J, Mandambwe C, et al
    Use of local data to evaluate TB contact investigation in Malawi.
    Int J Tuberc Lung Dis. 2023;27:408-410.
    PubMed    


  113. TANG J, Tang Z, Feng C, Tang Q, et al
    Efficacy and safety of video-assisted thoracoscopic surgery for pulmonary TB.
    Int J Tuberc Lung Dis. 2023;27:387-394.
    PubMed     Abstract available


  114. MAUGANS C, Loveday M, Hlangu S, Waitt C, et al
    Best practices for the care of pregnant people living with TB.
    Int J Tuberc Lung Dis. 2023;27:357-366.
    PubMed     Abstract available


  115. TAGUIBAO C, Lailo JM, Neukom J, Gones V, et al
    Digital survey results on pharmacy access to fixed-dose combination drugs for TB in Indonesia.
    Int J Tuberc Lung Dis. 2023;27:422-424.
    PubMed    


  116. MOE S, Rekart ML, Hernandez D, Sholpan A, et al
    Primary bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Int J Tuberc Lung Dis. 2023;27:381-386.
    PubMed     Abstract available


  117. AHMED R, Osman N, Noory B, Osman R, et al
    Prevalence and determinants of chronic respiratory diseases in adults in Sudan.
    Int J Tuberc Lung Dis. 2023;27:373-380.
    PubMed     Abstract available


  118. PAREDES JL, Picon V, Reynolds L, Ugarte-Gil C, et al
    Impact of the COVID-19 pandemic on TB care in Peru.
    Int J Tuberc Lung Dis. 2023;27:411-413.
    PubMed    


  119. MUTEMBA CM, Schindele A, Munyangaju I, Ramanlal N, et al
    Contribution of Xpert((R)) MTB/RIF to pediatric TB diagnosis in Mozambique.
    Int J Tuberc Lung Dis. 2023;27:419-421.
    PubMed    


    April 2023
  120. GRIJOTA-CAMINO MD, Perez-Recio S, Trapero C, Luque MJ, et al
    Identifying gaps in the cascade of care for latent TB infection in a low-incidence setting.
    Int J Tuberc Lung Dis. 2023;27:315-321.
    PubMed     Abstract available


  121. VELEN K, Nguyen TA, Pham CD, Le HT, et al
    The effect of medication event reminder monitoring on treatment adherence of TB patients.
    Int J Tuberc Lung Dis. 2023;27:322-328.
    PubMed     Abstract available


  122. BOLHUIS MS, Akkerman OW, Sturkenboom MGG, van Boven JFM, et al
    Bedaquiline exposure in people with drug-resistant TB treated for diabetes: analysis of two phase 2 trials.
    Int J Tuberc Lung Dis. 2023;27:335-337.
    PubMed    


  123. GOLETTI D, Pisapia R, Fusco FM, Aiello A, et al
    Epidemiology, pathogenesis, clinical presentation and management of TB in patients with HIV and diabetes.
    Int J Tuberc Lung Dis. 2023;27:284-290.
    PubMed     Abstract available


  124. MIGLIORI GB, Blackbourn HD
    Post-TB lung disease - the rationale for a Clinical Statement.
    Int J Tuberc Lung Dis. 2023;27:243-244.
    PubMed    


  125. CAMPBELL JR, Chan ED, Anderson LF, Bonnet M, et al
    Association of smoking and alcohol use with rifampin-resistant TB treatment outcomes.
    Int J Tuberc Lung Dis. 2023;27:338-340.
    PubMed    


  126. SACHDEVA KS, Bhatnagar AK, Bhaskar A, Singla N, et al
    QTc prolongation with bedaquiline treatment for drug-resistant pulmonary TB in a programmatic setting.
    Int J Tuberc Lung Dis. 2023;27:329-331.
    PubMed    


  127. KAZIBWE A, Kyazze AP, Ssekamatte P, Mutebi EI, et al
    TB infection in adults with diabetes mellitus in Uganda.
    Int J Tuberc Lung Dis. 2023;27:308-314.
    PubMed     Abstract available


  128. NIGHTINGALE R, Carlin F, Meghji J, McMullen K, et al
    Post-TB health and wellbeing.
    Int J Tuberc Lung Dis. 2023;27:248-283.
    PubMed     Abstract available


  129. MANGAN JM, Burzynski J, deCastro BR, Salerno MM, et al
    Challenges associated with electronic and in-person directly observed therapy during a randomized trial.
    Int J Tuberc Lung Dis. 2023;27:298-307.
    PubMed     Abstract available


  130. KINTU TM, Mwanahamisi BS, Muwanguzi M, Kyagambiddwa T, et al
    Unfavorable treatment outcomes among patients with drug-resistant TB in Uganda.
    Int J Tuberc Lung Dis. 2023;27:291-297.
    PubMed     Abstract available


    March 2023
  131. COLA JP, Nascimento do Prado T, Alves KBA, Lapa E Silva JR, et al
    Factors associated with non-completion of TB preventive treatment in Brazil.
    Int J Tuberc Lung Dis. 2023;27:215-220.
    PubMed     Abstract available


  132. HUDDART S, Asege L, Jaganath D, Golla M, et al
    Continuous cough monitoring: a novel digital biomarker for TB diagnosis and treatment response monitoring.
    Int J Tuberc Lung Dis. 2023;27:221-222.
    PubMed    


  133. YAACOUB H, Farhat AM, Najjar-Pellet J, Zgheib J, et al
    Planning for TB elimination in Lebanon.
    Int J Tuberc Lung Dis. 2023;27:171-174.
    PubMed    


  134. KWON YS, Jang JG, Lee J, Choi KJ, et al
    Risk factors for peripheral neuropathy in patients on linezolid-containing regimens for drug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:232-234.
    PubMed    


  135. PALACIOS CF, Hough MA, Shrestha R, Moll AP, et al
    Perceived stigma related to TB preventive therapy.
    Int J Tuberc Lung Dis. 2023;27:209-214.
    PubMed     Abstract available


  136. AKKERMAN OW, van Het Hof S, de Vries G, van Crevel R, et al
    Characteristics and mortality of central nervous system TB in the Netherlands: a 15-year comparison with other forms of TB.
    Int J Tuberc Lung Dis. 2023;27:237-239.
    PubMed    


  137. HUAROTO L, Huaman MA, Mugruza R, Ticona C, et al
    Active case-finding of pulmonary TB in an urban emergency department.
    Int J Tuberc Lung Dis. 2023;27:202-208.
    PubMed     Abstract available


  138. ADEWOLE OO, Omotoso BA, Ogunsina M, Aminu A, et al
    Atorvastatin accelerates Mycobacterium tuberculosis clearance in pulmonary TB: a randomised phase IIA trial.
    Int J Tuberc Lung Dis. 2023;27:226-228.
    PubMed    


  139. MALIK AA, Jaswal M, Siddiqui S, Amanullah F, et al
    Role of symptom and chest X-ray screening in evaluating child household contacts for pulmonary TB.
    Int J Tuberc Lung Dis. 2023;27:235-236.
    PubMed    


  140. TRAUER JM
    Targeted TB control in migrants to low-burden countries.
    Int J Tuberc Lung Dis. 2023;27:169-170.
    PubMed    


  141. MARTINEZ-GARCIA MA, Guan WJ, de-la-Rosa D, Athanazio R, et al
    Post-TB bronchiectasis: from pathogenesis to rehabilitation.
    Int J Tuberc Lung Dis. 2023;27:175-181.
    PubMed     Abstract available


  142. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
    Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field.
    Int J Tuberc Lung Dis. 2023;27:189-194.
    PubMed     Abstract available


  143. DAMARAJU V, Singh N, Garg M, Kathirvel S, et al
    Effect of prior pulmonary TB on low-dose computed tomography during lung cancer screening.
    Int J Tuberc Lung Dis. 2023;27:223-225.
    PubMed    


  144. SPRUIJT I, Erkens C, Greenaway C, Mulder C, et al
    Reducing the burden of TB among migrants to low TB incidence countries.
    Int J Tuberc Lung Dis. 2023;27:182-188.
    PubMed     Abstract available


  145. BAIK Y, Nakasolya O, Isooba D, Mukiibi J, et al
    Cost to perform door-to-door universal sputum screening for TB in a high-burden community.
    Int J Tuberc Lung Dis. 2023;27:195-201.
    PubMed     Abstract available


    February 2023
  146. CHUNG C, Shin JE, Jeon D, Kang H, et al
    Treatment outcomes and safety of bedaquiline, delamanid, and linezolid in multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:151-153.
    PubMed    


  147. GOMES I, Garg T, Churchyard G, Gupta A, et al
    The cascade of care for household contacts of people with drug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:154-156.
    PubMed    


  148. TOCHAENG C, Eksombatchai D, Boonsarngsuk V
    Factors associated with false-negative for T-SPOT.TB in patients with TB disease.
    Int J Tuberc Lung Dis. 2023;27:128-134.
    PubMed     Abstract available


  149. ALKABAB Y, Warkentin J, Cummins J, Katz B, et al
    Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus.
    Int J Tuberc Lung Dis. 2023;27:135-139.
    PubMed     Abstract available


  150. FORSMAN LD, Alffenaar JWC
    Diabetes mellitus and TB - finding strategies to reduce the double burden of disease.
    Int J Tuberc Lung Dis. 2023;27:91-93.
    PubMed    


  151. BARKER M, Gunther A, Wurps H, Gebhardt A, et al
    Ultrasound-guided lymph node biopsy in smear-negative children and adolescents with suspected TB.
    Int J Tuberc Lung Dis. 2023;27:164-165.
    PubMed    


  152. BOLSTERLI E, Keller PM, Suter-Riniker F, Kruger L, et al
    A comparison of bronchoalveolar lavage and gastric aspirate for diagnosis of paediatric TB.
    Int J Tuberc Lung Dis. 2023;27:148-150.
    PubMed    


  153. VILLA S, Carugati M, Rubach MP, Cleaveland S, et al
    'One Health approach to end zoonotic TB.
    Int J Tuberc Lung Dis. 2023;27:101-105.
    PubMed     Abstract available


  154. BALTAS I, Sturdy A, Kavallieros K, McGregor A, et al
    Diabetes mellitus is not a predictor of poor TB treatment outcomes.
    Int J Tuberc Lung Dis. 2023;27:140-145.
    PubMed     Abstract available


  155. CHUKWUOGO O, Odume B, Ogbudebe C, Useni S, et al
    Strategic approach to optimisation of TB contact investigation in Nigeria.
    Int J Tuberc Lung Dis. 2023;27:161-163.
    PubMed    


  156. PAUDEL K, Nalutaaya A, Robsky KO, Kitonsa PJ, et al
    The impact of time at home on potential yield of home-based TB contact investigation.
    Int J Tuberc Lung Dis. 2023;27:121-127.
    PubMed     Abstract available


  157. KOESOEMADINATA RC, McAllister SM, Soetedjo NNM, Santoso P, et al
    Diabetes characteristics and long-term management needs in diabetic TB patients.
    Int J Tuberc Lung Dis. 2023;27:113-120.
    PubMed     Abstract available


  158. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
    Extemporaneously compounded liquid formulations of clofazimine.
    Int J Tuberc Lung Dis. 2023;27:106-112.
    PubMed     Abstract available


  159. GENADE LP, Kahamba T, Scott L, Tempia S, et al
    Co-testing a single sputum specimen for TB and SARS-CoV-2.
    Int J Tuberc Lung Dis. 2023;27:146-147.
    PubMed    


    January 2023
  160. KHAN U, Guglielmetti L
    Tailored TPT for drug-resistant TB - promoting equity and access to optimal care.
    Int J Tuberc Lung Dis. 2023;27:89b-90.
    PubMed    


  161. MANSOOR H, Hirani N, Chavan V, Das M, et al
    Clinical utility of target-based next-generation sequencing for drug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:41-48.
    PubMed     Abstract available


  162. GILLESPIE SH
    Improving outcomes for multidrug-resistant TB: the role of integrated systems.
    Int J Tuberc Lung Dis. 2023;27:1-2.
    PubMed    


  163. SEHGAL IS, Muthu V, Agarwal R
    Aspergillus infection is an important complication of post-TB bronchiectasis.
    Int J Tuberc Lung Dis. 2023;27:89a-89.
    PubMed    


  164. OLARU ID, Beliz Meier M, Schumacher SG, Prodanovic N, et al
    Co-administration of treatment for drug-resistant TB and hepatitis C.
    Int J Tuberc Lung Dis. 2023;27:66-68.
    PubMed    


  165. FELKER I, Trajman A
    Shorter regimens for multidrug-/rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:3-4.
    PubMed    


  166. KWON YS, Shin JE, Kang H, Jeon D, et al
    Treatment outcomes of multidrug-resistant TB with selective use of new drugs.
    Int J Tuberc Lung Dis. 2023;27:55-60.
    PubMed     Abstract available


  167. ZENG C, Mitnick CD, Hewison C, Bastard M, et al
    Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:34-40.
    PubMed     Abstract available


  168. CANTERA JL, Rashid AA, Lillis LM, Peck RB, et al
    Isolation and purification of lipoarabinomannan from urine of adults with active TB.
    Int J Tuberc Lung Dis. 2023;27:75-77.
    PubMed    


  169. KNUDSEN S, Babu SP, Ramakrishnan J, Jenkins HE, et al
    M. tuberculosis infection before, during and after pregnancy.
    Int J Tuberc Lung Dis. 2023;27:72-74.
    PubMed    


  170. ATSHEMYAN H, Khachatryan N, Manukyan A, Khachatryan A, et al
    Implementation of modified, all-oral shorter TB regimens in Armenia.
    Int J Tuberc Lung Dis. 2023;27:84-85.
    PubMed    


  171. BUTOV D, Feshchenko Y, Chesov D, Myasoedov V, et al
    National survey on the impact of the war in Ukraine on TB diagnostics and treatment services in 2022.
    Int J Tuberc Lung Dis. 2023;27:86-88.
    PubMed    


  172. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
    Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:13-18.
    PubMed     Abstract available


  173. MAH JK, Lieu A, Fisher D, Lim RK, et al
    Impact of the COVID-19 pandemic on the epidemiology of TB in a low-incidence setting.
    Int J Tuberc Lung Dis. 2023;27:69-71.
    PubMed    


  174. COX SR, Padmapriyadarsini C, Mave V, Seth B, et al
    Characterising cause of death among people treated for drug-susceptible TB in India.
    Int J Tuberc Lung Dis. 2023;27:78-80.
    PubMed    


  175. JAW-TSAI S, Barry R, Pande PG, Taneja R, et al
    Comparison of pharmacokinetics and bioavailability of bedaquiline fumarate, benzoate and maleate in dogs.
    Int J Tuberc Lung Dis. 2023;27:28-33.
    PubMed     Abstract available


  176. DE HAAS P, Nhung NV, Hng NT, Hoa NB, et al
    Introduction of the Simple One-Step stool Xpert Ultra method to detect TB in children and adults.
    Int J Tuberc Lung Dis. 2023;27:19-27.
    PubMed     Abstract available


    December 2022
  177. NOESKE J, Kuaban C
    Tailored TB preventive treatment for drug-resistant TB - failing the test for appropriateness?
    Int J Tuberc Lung Dis. 2022;26:1198.
    PubMed    


  178. ALFFENAAR JWC, Marais BJ, Touw DJ
    Paediatric formulations for the treatment of drug resistant TB: closing the gaps.
    Int J Tuberc Lung Dis. 2022;26:1097-1100.
    PubMed    


  179. IZUDI J, Sheira LA, Bajunirwe F, McCoy SI, et al
    Effect of 6-month vs. 8-month regimen on retreatment success for pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:1188-1190.
    PubMed    


  180. DATTA A, Mohapatra PR, Bhuniya S, Mishra B, et al
    TB treatment regimen for children: is a 4-month regimen really better than the 6-month regimen?
    Int J Tuberc Lung Dis. 2022;26:1197.
    PubMed    


  181. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
    Stable sugar and sugar-free suspensions of pretomanid.
    Int J Tuberc Lung Dis. 2022;26:1112-1117.
    PubMed     Abstract available


  182. DEVOID I, Sillah AK, Sutherland J, Owolabi O, et al
    The household economic burden of drug-susceptible TB diagnosis and treatment in The Gambia.
    Int J Tuberc Lung Dis. 2022;26:1162-1169.
    PubMed     Abstract available


  183. MEMANI B, Furin J, Cox H, Reuter A, et al
    A very sneaky bug: perspectives of front-line clinicians on whole-genome sequencing for drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:1180-1182.
    PubMed    


  184. CARTER EJ, Mungai B, Njoroge T, Masese A, et al
    Finding the missing children for TB care and prevention in Kenya.
    Int J Tuberc Lung Dis. 2022;26:1144-1150.
    PubMed     Abstract available


    November 2022
  185. GRANOZZI B, Bisognin F, Tadolini M, Lombardi G, et al
    IGRA test for TB in COVID-19: role of corticosteroids.
    Int J Tuberc Lung Dis. 2022;26:1088-1091.
    PubMed    


  186. SMITH-JEFFCOAT SE, Eisenach KD, Joloba M, Ssengooba W, et al
    Quantification of multidrug-resistant M. tuberculosis bacilli in sputum during the first 8 weeks of treatment.
    Int J Tuberc Lung Dis. 2022;26:1058-1064.
    PubMed     Abstract available


  187. GARCIA-GOEZ JF, Tello-Cajiao ME, Vargas-Potes CJ, Penagos-Luna R, et al
    Effect of biological therapies on TB treatment outcomes.
    Int J Tuberc Lung Dis. 2022;26:1077-1079.
    PubMed    


  188. DIEFENBACH-ELSTOB T, Rivest P, Benedetti A, Gordon C, et al
    Patterns and characteristics of TB among key risk groups in Canada, 1993-2018.
    Int J Tuberc Lung Dis. 2022;26:1041-1049.
    PubMed     Abstract available


  189. VELAYUTHAM B, Shah V, Mythily V, Gopalaswamy R, et al
    Factors influencing treatment outcomes in patients with isoniazid-resistant pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:1033-1040.
    PubMed     Abstract available


  190. WILLEMSTEIN IJM, de Vries G, Essink DR, Slump E, et al
    TB in migrants residing in the Netherlands for at least 5 years at diagnosis, 2003-2018.
    Int J Tuberc Lung Dis. 2022;26:1050-1057.
    PubMed     Abstract available


  191. KRISHNAN N, Siddiqi K, Dogar O, Gabe R, et al
    Predictors of long-term smoking abstinence in TB patients.
    Int J Tuberc Lung Dis. 2022;26:1074-1076.
    PubMed    


  192. BARRETT R, Creswell J, Sahu S, Qin ZZ, et al
    User perspectives on the use of X-rays and computer-aided detection for TB.
    Int J Tuberc Lung Dis. 2022;26:1083-1085.
    PubMed    


  193. TRAORE M, Nguhiu P, Telly N, Traore S, et al
    The high costs facing TB-affected households in Mali.
    Int J Tuberc Lung Dis. 2022;26:1071-1073.
    PubMed    


    October 2022
  194. AIA P, Viney K, Kal M, Kisomb J, et al
    The economic burden of TB faced by patients and affected families in Papua New Guinea.
    Int J Tuberc Lung Dis. 2022;26:934-941.
    PubMed     Abstract available


  195. MARAIS BJ, Bernays S, Schaaf HS, Fox GJ, et al
    Increasing TB preventive treatment in children.
    Int J Tuberc Lung Dis. 2022;26:903-905.
    PubMed    


  196. TYEKU N, Apolisi I, Daniels J, Beko B, et al
    Pediatric delamanid treatment for children with rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:986-988.
    PubMed    


  197. MENEZES D, Zenner D, Aldridge R, Anderson SR, et al
    Country differences and determinants of yield in programmatic migrant TB screening in four European countries.
    Int J Tuberc Lung Dis. 2022;26:942-948.
    PubMed     Abstract available


  198. CATES L, Codreanu A, Ciobanu N, Fosburgh H, et al
    Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova.
    Int J Tuberc Lung Dis. 2022;26:963-969.
    PubMed     Abstract available


  199. BLACKBOURN H, Tiberi S, Felker I
    Literature Highlights.
    Int J Tuberc Lung Dis. 2022;26:914-916.
    PubMed     Abstract available


  200. PORRETTA AD, Manga S, Pontali E
    TB care in prisons: the ongoing challenge.
    Int J Tuberc Lung Dis. 2022;26:906-907.
    PubMed    


  201. DIALLO A, Combary A, Bakyono R, Guene H, et al
    A 2020 baseline assessment for the monitoring of the End TB indicator of catastrophic costs in Burkina Faso.
    Int J Tuberc Lung Dis. 2022;26:970-977.
    PubMed     Abstract available


  202. ROUZIER V, Murrill M, Kim S, Naini L, et al
    Caregiver willingness to give TPT to children living with drug-resistant TB patients.
    Int J Tuberc Lung Dis. 2022;26:949-955.
    PubMed     Abstract available


  203. SCHWALB A, Emery JC, Houben RMGJ
    Use of chest radiography screening for TB: a re-evaluation of the Kolin study.
    Int J Tuberc Lung Dis. 2022;26:983-985.
    PubMed    


  204. FATIMA R, Yaqoob A, Qadeer E, Khan MA, et al
    Community- vs. hospital-based management of multidrug-resistant TB in Pakistan.
    Int J Tuberc Lung Dis. 2022;26:929-933.
    PubMed     Abstract available


  205. MANGOCHI P, Bossard C, Catacutan C, Van Laeken D, et al
    TB screening, prevention and treatment cascade in a Malawi prison.
    Int J Tuberc Lung Dis. 2022;26:956-962.
    PubMed     Abstract available


    September 2022
  206. FARIA N, Reis R
    Screening for TB infection: the operator s impact.
    Int J Tuberc Lung Dis. 2022;26:857-861.
    PubMed     Abstract available


  207. MOHAPATRA PR, Mishra B, Dutta A, Bhuniya S, et al
    Responding to WHO s 4-month regimen for drug-susceptible pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:898-899.
    PubMed    


  208. KHAN U, Guglielmetti L
    Evidence and ethical considerations for the treatment of contacts exposed to drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:900-901.
    PubMed    


  209. SABI I, Olomi W, Nkereuwem E, Togun T, et al
    Diagnosis of paediatric TB using Xpert((R)) MTB/RIF Ultra on fresh respiratory samples.
    Int J Tuberc Lung Dis. 2022;26:862-868.
    PubMed     Abstract available


  210. SANTOS AP, Silva DR, Miranda G, Braga MS, et al
    Xpert((R)) MTB/RIF Ultra: detection of extrapulmonary TB in a high-burden setting.
    Int J Tuberc Lung Dis. 2022;26:880-882.
    PubMed    


  211. DURET A, Olgemoeller F, Ferreras-Antolin L, Whittaker E, et al
    Paediatric TB care in the United Kingdom.
    Int J Tuberc Lung Dis. 2022;26:814-819.
    PubMed     Abstract available


  212. SHUKLA A, Bromage S, Dholakia Y, Hemler EC, et al
    Case-control study of vitamin D status and adult multidrug-resistant pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:826-834.
    PubMed     Abstract available


  213. CHO EJ, Kang MR, Kim JH, Lee JI, et al
    Evaluation of the MolecuTech((R)) REBA MTB-XMDR kit for detection of pre-extensively drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:869-874.
    PubMed     Abstract available


  214. SCHWALB A, Cachay R, Wright A, Phillips PPJ, et al
    Factors associated with screening failure and study withdrawal in multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:820-825.
    PubMed     Abstract available


  215. TABERNERO E, Rodrigo T, Garros J, Altube L, et al
    TB in the elderly: clinical features and outcomes.
    Int J Tuberc Lung Dis. 2022;26:842-849.
    PubMed     Abstract available


  216. KRAEF C, Yedilbayev A, Seguy N, Bentzon A, et al
    Uptake of the lateral flow urine LAM test in Europe and Central Asia.
    Int J Tuberc Lung Dis. 2022;26:835-841.
    PubMed     Abstract available


    August 2022
  217. WEBER SF, Ruby LC, Heller T, Hande M, et al
    TB disease patterns by HIV and diabetes status.
    Int J Tuberc Lung Dis. 2022;26:733-740.
    PubMed     Abstract available


  218. MALIK AA, Siddique M, Chandir S, Jaswal M, et al
    Travel reimbursements, distance to health facility and preventive treatment cascade for drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:789-791.
    PubMed    


  219. MAGOHE A, Kimario J, Lukmanji Z, Hendricks K, et al
    Randomized, controlled trial of a protein-calorie supplement for women coinfected with HIV-TB.
    Int J Tuberc Lung Dis. 2022;26:798-800.
    PubMed    


  220. JASWAL M, Farooq S, Madhani F, Noorani S, et al
    Implementing 3HP vs. IPT as TB preventive treatment in Pakistan.
    Int J Tuberc Lung Dis. 2022;26:741-746.
    PubMed     Abstract available


  221. CASALME DJO, Marcelo DB, Dela Cuesta DM, Tonquin M, et al
    Feasibility and acceptability of asynchronous VOT among patients with MDR-TB.
    Int J Tuberc Lung Dis. 2022;26:760-765.
    PubMed     Abstract available


  222. CHHABRA S, Ong CWM, Sotgiu G
    TB diagnosis and treatment during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2022;26:702-703.
    PubMed    


  223. VERGEER SB, Oldenkamp R, Senkoro M, Mfinanga S, et al
    Does distance to healthcare facility affect care-seeking for TB-related symptoms in Tanzania?
    Int J Tuberc Lung Dis. 2022;26:747-752.
    PubMed     Abstract available


  224. GEBRESELASSIE N, Falzon D, Zignol M, Viney K, et al
    Bridging the gap: key evidence needed to strengthen global policies to end TB.
    Int J Tuberc Lung Dis. 2022;26:704-707.
    PubMed    


  225. NAQVI S, Cantu Y, Ong Uti S, Cavazos D, et al
    Successes and challenges of latent TB screening and treatment in a high-prevalence US region.
    Int J Tuberc Lung Dis. 2022;26:720-726.
    PubMed     Abstract available


  226. KOKEBU DM, Ahmed S, Moodliar R, Chiang CY, et al
    Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB.
    Int J Tuberc Lung Dis. 2022;26:753-759.
    PubMed     Abstract available


  227. GIANNONI F, Lanni A, Iacobino A, Cirillo DM, et al
    Decreasing trend of drug-resistant TB in Italy.
    Int J Tuberc Lung Dis. 2022;26:775-783.
    PubMed     Abstract available


  228. REKART ML, Morshed T, Mulanda WK, Klieascikova J, et al
    Family directly observed therapy for children with drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:792-794.
    PubMed    


    July 2022
  229. ISMAIL F, Yousif A, Alfurjani M, Haq S, et al
    TB in eastern Libya: a decreasing trend in recent decades.
    Int J Tuberc Lung Dis. 2022;26:694-695.
    PubMed    


  230. BASHAM CA, Orr PH
    Monitoring TB program performance.
    Int J Tuberc Lung Dis. 2022;26:692-693.
    PubMed    


  231. NAIR P, Hasan T, Zaw KK, Allamuratova S, et al
    Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Int J Tuberc Lung Dis. 2022;26:658-663.
    PubMed     Abstract available


  232. CARVALHO ACC, Kritski AL
    Community-based intervention and health education to scale up TB preventive treatment for children.
    Int J Tuberc Lung Dis. 2022;26:587-589.
    PubMed    


  233. AKKERMAN OW, Duarte R, Tiberi S, Schaaf HS, et al
    Clinical standards for drug-susceptible pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:592-604.
    PubMed     Abstract available


  234. VAN DER WERF TS, Grobusch MP
    Clinical standards for drug-susceptible TB: putting patients first.
    Int J Tuberc Lung Dis. 2022;26:584-586.
    PubMed    


  235. NGUENHA D, Acacio S, Murias-Closas A, Ramanlal N, et al
    Prevalence and clinical characteristics of pulmonary TB among pregnant and post-partum women.
    Int J Tuberc Lung Dis. 2022;26:641-649.
    PubMed     Abstract available


  236. VARSHNEY K, Rusnak JC
    TB reporting declines in priority countries during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2022;26:681-683.
    PubMed    


  237. WEYENGA H, Onyango E, Katana AK, Pathmanathan I, et al
    Trends in TB and HIV care and treatment cascade, Kenya, 2008-2018.
    Int J Tuberc Lung Dis. 2022;26:623-628.
    PubMed     Abstract available


  238. MIGLIORI GB, Tiberi S
    WHO drug-resistant TB guidelines 2022: what is new?
    Int J Tuberc Lung Dis. 2022;26:590-591.
    PubMed    


  239. KAMBILI C, Rossenu S, Hoetelmans RMW, Birmingham E, et al
    Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:671-677.
    PubMed     Abstract available


    June 2022
  240. LAZARCHIK A, Nyaruhirira AU, Chiang CY, Wares F, et al
    Global availability of susceptibility testing for second-line anti-tuberculosis agents.
    Int J Tuberc Lung Dis. 2022;26:524-528.
    PubMed     Abstract available


  241. PELZER PT, Smit Y, Tiemersma EW, Huong NT, et al
    Does BCG vaccination protect against infection with M. tuberculosis?
    Int J Tuberc Lung Dis. 2022;26:529-536.
    PubMed     Abstract available


  242. SINHA P, Bhargava A, Carwile M, Cintron C, et al
    Undernutrition can no longer be an afterthought for global efforts to eliminate TB.
    Int J Tuberc Lung Dis. 2022;26:477-480.
    PubMed    


  243. BOEKELHEIDE K, Olugbosi M, Nedelman J, Everitt D, et al
    Male reproductive hormones in patients treated with pretomanid.
    Int J Tuberc Lung Dis. 2022;26:558-565.
    PubMed     Abstract available


  244. KANIGA K, Lounis N, Zhuo S, Bakare N, et al
    Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline.
    Int J Tuberc Lung Dis. 2022;26:571-573.
    PubMed    


  245. LAURSEN LL, Dahl VN, Wejse C
    Stool testing for pulmonary TB diagnosis in adults.
    Int J Tuberc Lung Dis. 2022;26:516-523.
    PubMed     Abstract available


  246. SHIN AY, Jekarl DW, Kim HW, Ha JH, et al
    Early line-probe assay using DNA specimens in patients with pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:509-515.
    PubMed     Abstract available


  247. NAUFAL F, Chaisson LH, Robsky KO, Delgado-Barroso P, et al
    Number needed to screen for TB in clinical, structural or occupational risk groups.
    Int J Tuberc Lung Dis. 2022;26:500-508.
    PubMed     Abstract available


  248. MALIK AA, Amanullah F
    Source case investigation can reduce the diagnostic gap for childhood TB.
    Int J Tuberc Lung Dis. 2022;26:566-567.
    PubMed    


    May 2022
  249. GRANOZZI B, Bisognin F, Lombardi G, Dal Monte P, et al
    TB mortality in low-incidence countries: can we reduce it further?
    Int J Tuberc Lung Dis. 2022;26:467-469.
    PubMed    


  250. GROSCHEL MI, van den Boom M, Dixit A, Skrahina A, et al
    Management of childhood MDR-TB in Europe and Central Asia: report of a Regional WHO meeting.
    Int J Tuberc Lung Dis. 2022;26:433-440.
    PubMed     Abstract available


  251. SHAMPUTA IC, Nguyen DTK, Burdo T, Dao G, et al
    Canadian immigrants awareness and perceptions of TB infection and TB.
    Int J Tuberc Lung Dis. 2022;26:454-456.
    PubMed    


  252. COOREY NJ, Kensitt L, Davies J, Keller E, et al
    Risk factors for TB in Australia and their association with delayed treatment completion.
    Int J Tuberc Lung Dis. 2022;26:399-405.
    PubMed     Abstract available


  253. KRITSKI AL, Viveiros M, Carvalho ACC
    Rapid molecular diagnostics to detect resistance to second-line anti-TB drugs.
    Int J Tuberc Lung Dis. 2022;26:385-387.
    PubMed    


  254. GANDHI R, Deepak KG, Verma G, Chaubey S, et al
    Engaging private pharmacies to help end TB in India.
    Int J Tuberc Lung Dis. 2022;26:457-459.
    PubMed    


  255. NINAN MM, Rupali P, Varghese GM, Shalini EB, et al
    Xpert Ultra in diagnosing extrapulmonary TB: accuracy and trace calls.
    Int J Tuberc Lung Dis. 2022;26:441-445.
    PubMed     Abstract available


  256. MALIK AA, Hussain H
    Preventive treatment for MDR-TB exposure in households.
    Int J Tuberc Lung Dis. 2022;26:466-467.
    PubMed    


  257. CAPEDING TPJ, Rosa JD, Lam H, Gaviola DG, et al
    Cost of TB prevention and treatment in the Philippines in 2017.
    Int J Tuberc Lung Dis. 2022;26:392-398.
    PubMed     Abstract available


  258. PALANI N, Premkumar M, Vaishnavee V, Dinesh V, et al
    Trends in rifampicin and isoniazid resistance in patients with presumptive TB.
    Int J Tuberc Lung Dis. 2022;26:446-453.
    PubMed     Abstract available


    April 2022
  259. MARCHESE V, Formenti B, Marchese L, Gregori N, et al
    COVID-19 effect on TB presentation and outcome.
    Int J Tuberc Lung Dis. 2022;26:375-377.
    PubMed    


  260. KIM JW, Vella C, Parvez W, Verma R, et al
    Impact of COVID-19 on the diagnosis and management of lung cancer and TB.
    Int J Tuberc Lung Dis. 2022;26:372-374.
    PubMed    


  261. ALLORANT A, Biswas S, Ahmed S, Wiens KE, et al
    Finding gaps in routine TB surveillance activities in Bangladesh.
    Int J Tuberc Lung Dis. 2022;26:356-362.
    PubMed     Abstract available


  262. SHIVAKUMAR SVBY, Padmapriyadarsini C, Chavan A, Paradkar M, et al
    Concomitant pulmonary disease is common among patients with extrapulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:341-347.
    PubMed     Abstract available


  263. HUGHES G, Bern H, Chiang CY, Goodall RL, et al
    QT prolongation in the STREAM Stage 1 Trial.
    Int J Tuberc Lung Dis. 2022;26:334-340.
    PubMed     Abstract available


  264. DEN BOON S, Lienhardt C, Zignol M, Schwartzman K, et al
    WHO target product profiles for TB preventive treatment.
    Int J Tuberc Lung Dis. 2022;26:302-309.
    PubMed     Abstract available


  265. ADAMASHVILI N, Baliashvili D, Kuchukhidze G, Salindri AD, et al
    Low BMI increases all-cause mortality rates in patients with drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:326-333.
    PubMed     Abstract available


  266. PRADHAN NN, Paradkar MS, Kagal A, Valvi C, et al
    Performance of Xpert((R)) MTB/RIF and Xpert((R)) Ultra for the diagnosis of tuberculous meningitis in children.
    Int J Tuberc Lung Dis. 2022;26:317-325.
    PubMed     Abstract available


  267. DOWDY DW, Islam MA
    Finding TB s "missing millions", one district at a time.
    Int J Tuberc Lung Dis. 2022;26:295.
    PubMed    


    March 2022
  268. SUMNER T, Jensen HT, Keogh-Brown MR, Vassall A, et al
    Time to integrate epidemiological and economic models for TB.
    Int J Tuberc Lung Dis. 2022;26:282-284.
    PubMed    


  269. MBELELE PM, Sabiiti W, Heysell SK, Sauli E, et al
    Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease.
    Int J Tuberc Lung Dis. 2022;26:276-278.
    PubMed    


  270. MUSONDA HK, Rose PC, Switala J, Schaaf HS, et al
    Paediatric admissions to a TB hospital: reasons for admission, clinical profile and outcomes.
    Int J Tuberc Lung Dis. 2022;26:217-223.
    PubMed     Abstract available


  271. MIGLIORI GB, Wu SJ, Matteelli A, Zenner D, et al
    Clinical standards for the diagnosis, treatment and prevention of TB infection.
    Int J Tuberc Lung Dis. 2022;26:190-205.
    PubMed     Abstract available


    February 2022
  272. TINOCO EM, Vasconcelos A, Alves F, Duarte R, et al
    Impact of COVID-19 on extrapulmonary TB and the benefit of decentralised TB services.
    Int J Tuberc Lung Dis. 2022;26:178-180.
    PubMed    


  273. ORTIZ-MARTINEZ Y, Rodriguez-Morales AJ, Henao-Martinez AF
    Decreased notification of TB cases during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2022;26:177-178.
    PubMed    


  274. SCHIZA V, Kruse M, Xiao Y, Kar S, et al
    Impact of the COVID-19 pandemic on TB infection testing.
    Int J Tuberc Lung Dis. 2022;26:174-176.
    PubMed    


  275. GUREVA T, Turkova A, Yablokova E, Smirnova P, et al
    Fluoroquinolone preventive therapy for children exposed to MDR-TB.
    Int J Tuberc Lung Dis. 2022;26:171-173.
    PubMed    


  276. BOHLBRO AS, Patsche CB, Mendes AM, Sifna A, et al
    A self-rated health score predicts severe disease and high mortality in patients with pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:158-165.
    PubMed     Abstract available


  277. MOHR-HOLLAND E, Daniels J, Reuter A, Rodriguez CA, et al
    Early mortality during rifampicin-resistant TB treatment.
    Int J Tuberc Lung Dis. 2022;26:150-157.
    PubMed     Abstract available


  278. BEAUMONT AL, Doumbia A, Chateau N, Meynard JL, et al
    Why are people still dying of drug-susceptible TB in Paris in the 21(st) century?
    Int J Tuberc Lung Dis. 2022;26:142-149.
    PubMed     Abstract available


  279. LOPEZ-VARELA E, Garcia-Prats AJ, Seddon JA, Draper HR, et al
    Treatment outcomes and safety in children with rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:133-141.
    PubMed     Abstract available


  280. BURHAN E, Soepandi PZ, Isbaniah F, Damayanti K, et al
    Determinants of treatment outcomes in patients with multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:126-132.
    PubMed     Abstract available


  281. HOSSAIN MD, Rahim MA, Islam N, Afroze F, et al
    TB prevalence among patients with diabetes in Bangladesh.
    Int J Tuberc Lung Dis. 2022;26:119-125.
    PubMed     Abstract available


  282. KHAWCHAROENPORN T, Noisang K
    Incomplete contact investigation and risk of developing TB among healthcare professionals.
    Int J Tuberc Lung Dis. 2022;26:111-118.
    PubMed     Abstract available


  283. APRIANI L, Koesoemadinata RC, Bastos ML, Wulandari DA, et al
    Implementing the 4R and 9H regimens for TB preventive treatment in Indonesia.
    Int J Tuberc Lung Dis. 2022;26:103-110.
    PubMed     Abstract available


  284. ILAIWY G, Heysell SK, Thomas TA
    National approaches to TB care in adolescents.
    Int J Tuberc Lung Dis. 2022;26:96-102.
    PubMed     Abstract available


  285. SILVA DR, de Queiroz Mello FC
    Improving outcomes for multidrug-resistant TB treatment.
    Int J Tuberc Lung Dis. 2022;26:93-95.
    PubMed    


  286. BARRETT J
    Why are people still dying from TB in low-burden countries?
    Int J Tuberc Lung Dis. 2022;26:91-92.
    PubMed    


  287. HARRIES AD, Zellweger JP
    Protecting healthcare workers from TB.
    Int J Tuberc Lung Dis. 2022;26:89-90.
    PubMed    


  288. GRAHAM SM, Amanullah F
    Updated guidelines for child and adolescent TB.
    Int J Tuberc Lung Dis. 2022;26:81-84.
    PubMed    


  289. LANGE C, Kay A, Mandalakas AM
    The need for effective drugs for TB prevention: set your goals high, and don t stop till you get there.
    Int J Tuberc Lung Dis. 2022;26:85-88.
    PubMed    


    January 2022
  290. TADOLINI M, Onozaki I
    National TB prevalence surveys in the COVID-19 era.
    Int J Tuberc Lung Dis. 2022;26:4-5.
    PubMed    


  291. SINHA P, White LF, Hochberg NS, Cegielski JP, et al
    Avoiding pitfalls in calculating the population attributable fraction of undernutrition for TB.
    Int J Tuberc Lung Dis. 2022;26:80.
    PubMed    


  292. KLAOS K, Holicka Y, Groenheit R, Kodmon C, et al
    Current state of national TB laboratory networks in Europe: achievements and challenges.
    Int J Tuberc Lung Dis. 2022;26:71-73.
    PubMed    


  293. OJUAWO O, Piracha S, Irshad S, Mirza M, et al
    Tuberculous mastitis in a low-incidence setting: should respiratory physicians be concerned?
    Int J Tuberc Lung Dis. 2022;26:69-70.
    PubMed    


  294. PETRUCCIOLI E, Farroni C, Cuzzi G, Vanini V, et al
    VIDAS((R)) TB-IGRA reagents induce a CD4(+) and CD8(+) T-cell IFN-gamma response for both TB infection and active TB.
    Int J Tuberc Lung Dis. 2022;26:65-68.
    PubMed    


  295. CHIPINDURO M, Timire C, Chirenda J, Matambo R, et al
    TB prevalence in Zimbabwe: a national cross-sectional survey, 2014.
    Int J Tuberc Lung Dis. 2022;26:57-64.
    PubMed     Abstract available


  296. ACOSTA J, Flores P, Alarcon M, Grande-Ortiz M, et al
    A randomised controlled trial to evaluate a medication monitoring system for TB treatment.
    Int J Tuberc Lung Dis. 2022;26:44-49.
    PubMed     Abstract available


    December 2021
  297. ZAMANI S, Honarvar MR, Behnampour N, Sheikhy M, et al
    Decline in TB incidence during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2021;25:1043-1044.
    PubMed    


  298. SUMNER T, Fiore-Gartland A, Hatherill M, Houben RMGJ, et al
    The effect of new Mycobacterium tuberculosis infection on the sensitivity of prognostic TB signatures.
    Int J Tuberc Lung Dis. 2021;25:1001-1005.
    PubMed     Abstract available


  299. SARDA R, Ray A
    Pulmonary TB and chronic pulmonary aspergillosis.
    Int J Tuberc Lung Dis. 2021;25:1042-1043.
    PubMed    


  300. TESFAHUN H, Moussally K, Al-Ani NA, Al-Salhi LG, et al
    Introduction of new drugs for drug-resistant TB in Iraq.
    Int J Tuberc Lung Dis. 2021;25:1041-1042.
    PubMed    


  301. CHATTERJEE S, Toshniwal MN, Bhide P, Sachdeva KS, et al
    Costs of TB services in India (No 1).
    Int J Tuberc Lung Dis. 2021;25:1013-1018.
    PubMed     Abstract available


  302. ZHU H, Xie L, Liu ZQ, Wang B, et al
    Population pharmacokinetics of bedaquiline in patients with drug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:1006-1012.
    PubMed     Abstract available


  303. NIKOLENKA A, Mansjo M, Skrahina A, Hurevich H, et al
    Whole-genome sequencing differentiates relapse from re-infection in TB.
    Int J Tuberc Lung Dis. 2021;25:995-1000.
    PubMed     Abstract available


  304. LEE JJ, Kang HY, Lee WI, Cho SY, et al
    Efflux pump gene expression study using RNA-seq in multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:974-981.
    PubMed     Abstract available


  305. TELISINGHE L, Shaweno D, Hayes RJ, Dodd PJ, et al
    The effect of systematic screening of the general population on TB case notification rates.
    Int J Tuberc Lung Dis. 2021;25:964-973.
    PubMed     Abstract available


    November 2021
  306. ANTONY S, Bodhanwala M, Shah I
    Clinical profile and outcomes of paediatric central nervous system tuberculomas.
    Int J Tuberc Lung Dis. 2021;25:953-955.
    PubMed    


  307. FUKUSHIMA K, Akagi K, Kondoh A, Kubo T, et al
    Evaluation of QFT-Plus performance using blood samples stored at room temperature.
    Int J Tuberc Lung Dis. 2021;25:948-949.
    PubMed    


  308. WOLTERS BA, Aartsma Y, Jansen K, van Hest R, et al
    Travel history and challenges of screening for latent TB infection in child asylum seekers.
    Int J Tuberc Lung Dis. 2021;25:945-947.
    PubMed    


  309. CHRISTOPHER DJ, Coelho V, Ebby GS, Shankar D, et al
    Incremental yield of Xpert((R)) MTB/RIF Ultra over Xpert((R)) MTB/RIF in the diagnosis of extrapulmonary TB.
    Int J Tuberc Lung Dis. 2021;25:939-944.
    PubMed     Abstract available


  310. GATECHOMPOL S, Sophonphan J, Kerr SJ, Ubolyam S, et al
    Monocyte-to-lymphocyte ratio as a predictor of TB among people living with HIV.
    Int J Tuberc Lung Dis. 2021;25:933-938.
    PubMed     Abstract available


  311. KASWA M, Minga G, Nkiere N, Mingiedi B, et al
    The economic burden of TB-affected households in DR Congo.
    Int J Tuberc Lung Dis. 2021;25:923-932.
    PubMed     Abstract available


  312. STIEBER F, Howard J, Manissero D, Boyle J, et al
    Evaluation of a lateral-flow nanoparticle fluorescence assay for TB infection diagnosis.
    Int J Tuberc Lung Dis. 2021;25:917-922.
    PubMed     Abstract available


  313. MURITHI W, Click ES, McCarthy KD, Okeyo E, et al
    Need for caution when interpreting Xpert((R)) MTB/RIF results for rifampin resistance among children.
    Int J Tuberc Lung Dis. 2021;25:911-916.
    PubMed     Abstract available


  314. LUAN L, Fraisse P, Cordel H, Charlois C, et al
    Screening for active and latent TB among migrants in France.
    Int J Tuberc Lung Dis. 2021;25:903-910.
    PubMed     Abstract available


  315. WINCKLER JL, Schaaf HS, Draper HR, McIlleron H, et al
    Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:896-902.
    PubMed     Abstract available


  316. TAAFFE J, Croda J, Moultrie H, Silva DS, et al
    Advancing TB research using digitized programmatic data.
    Int J Tuberc Lung Dis. 2021;25:890-895.
    PubMed     Abstract available


  317. BOEREE MJ, Lange C, Thwaites G, Paton N, et al
    UNITE4TB: a new consortium for clinical drug and regimen development for TB.
    Int J Tuberc Lung Dis. 2021;25:886-889.
    PubMed    


  318. OCHERETINA O, Brandao AP, Pang Y, Rodrigues C, et al
    Impact of the bacillary load on the accuracy of rifampicin resistance results by Xpert((R)) MTB/RIF.
    Int J Tuberc Lung Dis. 2021;25:881-885.
    PubMed    


  319. ALFFENAAR JC, Marais BJ, Thomas TA
    Is a high dose sufficient to achieve high isoniazid exposure in children affected by multidrug-resistant TB?
    Int J Tuberc Lung Dis. 2021;25:879-880.
    PubMed    


    October 2021
  320. SEKANDI JN, Tucker EG, Zalwango S, Buregyeya E, et al
    Digital technologies and loss to follow-up for TB patients.
    Int J Tuberc Lung Dis. 2021;25:871-872.
    PubMed    


  321. HASSAN L, Ali SM, Iqbal W, Baig S, et al
    Automated detection and reduction of stigma in online discussions about TB.
    Int J Tuberc Lung Dis. 2021;25:869-870.
    PubMed    


  322. ARENAS-MIRAS M, Sanchez-Martinez F, Jove-Caballe N, Villar-Garcia J, et al
    Clinical experience of TB in patients treated with anti-TNF-alpha.
    Int J Tuberc Lung Dis. 2021;25:866-868.
    PubMed    


  323. TAHSEEN S, Khanzada FM, Hussain A, Akhtar N, et al
    Phenotypic vs. genotypic resistance to fluoroquinolones in rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:861-863.
    PubMed    


  324. EJO M, Van Deun A, Nunn A, Meredith S, et al
    Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial.
    Int J Tuberc Lung Dis. 2021;25:839-845.
    PubMed     Abstract available


  325. BLACK M, Da Silva P, Scott L
    Rifampicin-resistant TB: discordance between Xpert((R)) MTB/RIF and MTBDRplus results.
    Int J Tuberc Lung Dis. 2021;25:832-838.
    PubMed     Abstract available


  326. OXLADE O, den Boon S, Menzies D, Falzon D, et al
    TB preventive treatment in high- and intermediate-incidence countries: research needs for scale-up.
    Int J Tuberc Lung Dis. 2021;25:823-831.
    PubMed     Abstract available


  327. PURCHASE S, Batist E, Mmile N, Nkosi S, et al
    Challenges in recruiting children to a multidrug-resistant TB prevention trial.
    Int J Tuberc Lung Dis. 2021;25:814-822.
    PubMed     Abstract available


    September 2021
  328. KOZINSKA M, Podlasin R, Ropelewska-Lacka K, Wojtycha-Kwasnica B, et al
    TB and COVID-19 coinfection.
    Int J Tuberc Lung Dis. 2021;25:776-777.
    PubMed    


  329. MOHR-HOLLAND E, Hacking D, Daniels J, Scott V, et al
    Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19.
    Int J Tuberc Lung Dis. 2021;25:772-775.
    PubMed    


  330. GIGANTE AR, Sousa M, Aguiar A, Pinto M, et al
    The impact of COVID-19 on the TB response: data from the field.
    Int J Tuberc Lung Dis. 2021;25:769-771.
    PubMed    


  331. SHIN JE, Jo KW, O YJ, Jeon D, et al
    Impact of revised definitions for extensively drug-resistant TB on disease classification.
    Int J Tuberc Lung Dis. 2021;25:766-768.
    PubMed    


  332. GUTIERREZ A, Isidro A, Herrerin J, Hinojosa J, et al
    Meningeal TB in a mummified child from 4,000 years ago.
    Int J Tuberc Lung Dis. 2021;25:761-762.
    PubMed    


  333. KAMOLWAT P, Nonghanphithak D, Chaiprasert A, Smithtikarn S, et al
    Diagnostic performance of whole-genome sequencing for identifying drug-resistant TB in Thailand.
    Int J Tuberc Lung Dis. 2021;25:754-760.
    PubMed     Abstract available


  334. HUDDART S, Ingawale P, Edwin J, Jondhale V, et al
    TB case fatality and recurrence in a private sector cohort in Mumbai, India.
    Int J Tuberc Lung Dis. 2021;25:738-746.
    PubMed     Abstract available


  335. MOODLIAR R, Aksenova V, Frias MVG, van de Logt J, et al
    Bedaquiline for multidrug-resistant TB in paediatric patients.
    Int J Tuberc Lung Dis. 2021;25:716-724.
    PubMed     Abstract available


  336. MURPHY RA, Douglas-Jones B, Mucinya G, Sunpath H, et al
    Expanding the use of dolutegravir-based antiretroviral therapy in multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:696-700.
    PubMed     Abstract available


  337. CHESOV D, Makhanda G, Furin J
    Tackling the many layers of stigma is essential for the "End TB Strategy".
    Int J Tuberc Lung Dis. 2021;25:683-684.
    PubMed    


    August 2021
  338. RANAIVOMANANA P, Knoblauch AM, Razafimahatratra MC, Raherinandrasana AH, et al
    Pulmonary and pleural TB prevalence in pregnant women.
    Int J Tuberc Lung Dis. 2021;25:668-670.
    PubMed    


  339. EDDY JJ, Seth B, White LF, Sulis CA, et al
    Decreasing time spent in airborne infection isolation during TB testing.
    Int J Tuberc Lung Dis. 2021;25:665-667.
    PubMed    


  340. CLARKSON MC, McQuaid CF, Houben RM, Kranzer K, et al
    Better data for country-level TB resource allocation are urgently required.
    Int J Tuberc Lung Dis. 2021;25:662-664.
    PubMed    


  341. PERRY A, Chitnis A, Chin A, Hoffmann C, et al
    Real-world implementation of video-observed therapy in an urban TB program in the United States.
    Int J Tuberc Lung Dis. 2021;25:655-661.
    PubMed     Abstract available


  342. SMITH AGC, Gujabidze M, Avaliani T, Blumberg HM, et al
    Clinical outcomes among patients with tuberculous meningitis receiving intensified treatment regimens.
    Int J Tuberc Lung Dis. 2021;25:632-639.
    PubMed     Abstract available


  343. SHARMA K, Sharma M, Modi M, Singla N, et al
    Comparative analysis of Truenat MTB Plus and Xpert((R)) Ultra in diagnosing tuberculous meningitis.
    Int J Tuberc Lung Dis. 2021;25:626-631.
    PubMed     Abstract available


  344. CAMPBELL JR, Katamba A, Oxlade O, Schwartzman K, et al
    Improving country-level modelling to support TB prevention and care.
    Int J Tuberc Lung Dis. 2021;25:607-608.
    PubMed    


  345. DONOVAN J, Walker TM
    Diagnosing tuberculous meningitis: a testing process.
    Int J Tuberc Lung Dis. 2021;25:605-606.
    PubMed    


    July 2021
  346. AMOUR M, von Reyn CF
    A new paradigm: testing household contacts of adolescents with incident TB infection.
    Int J Tuberc Lung Dis. 2021;25:599b-600.
    PubMed    


  347. RODRIGUEZ CA, Brooks MB, Aibana O, Mitnick CD, et al
    Sputum culture conversion definitions and analytic practices for multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:596-598.
    PubMed    


  348. ERISA KC, Robsky KO, Kitonsa PJ, Nalutaaya A, et al
    Low prevalence of diabetes mellitus in TB patients and the community in urban Uganda.
    Int J Tuberc Lung Dis. 2021;25:590-592.
    PubMed    


  349. DOUGLAS-JONES B, Mohr-Holland E, Mema N, Mathee S, et al
    A home-based care programme for rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:587-589.
    PubMed    


  350. HABIB SS, Malik AA, Khan U, Khowaja S, et al
    Impact of upfront Xpert testing on time to treatment initiation for multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:584-586.
    PubMed    


  351. MORAN A, Lebona L, Makgopa G, Nkwane Y, et al
    One size does not fit all: reaching agricultural workers in South Africa with TB services.
    Int J Tuberc Lung Dis. 2021;25:573-578.
    PubMed     Abstract available


  352. YANGTHARA B, Wutthigate P, Roongmaitree S, Siripattanapipong P, et al
    Nosocomial TB in two neonatal intensive care units at a tertiary care centre: infection risk and outcomes.
    Int J Tuberc Lung Dis. 2021;25:567-572.
    PubMed     Abstract available


  353. BLACK DA, McBrien SW, Gersh J, Ghassemieh B, et al
    TB risk by time since U.S. entry among non-U.S.-born residents of Washington State, USA.
    Int J Tuberc Lung Dis. 2021;25:560-566.
    PubMed     Abstract available


  354. FEUTH T, Patovirta RL, Grierson S, Danilovits M, et al
    Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines.
    Int J Tuberc Lung Dis. 2021;25:554-559.
    PubMed     Abstract available


  355. LARGEN A, Ayala A, Khurana R, Katz DJ, et al
    Evaluation of point-of-care algorithms to detect diabetes during screening for latent TB infection.
    Int J Tuberc Lung Dis. 2021;25:547-553.
    PubMed     Abstract available


  356. BALUKU JB, Nuwagira E, Bongomin F, Denning DW, et al
    Pulmonary TB and chronic pulmonary aspergillosis: clinical differences and similarities.
    Int J Tuberc Lung Dis. 2021;25:537-546.
    PubMed     Abstract available


  357. SHARMA M, Onozaki I, Nunn P
    TB in older people in Asia: why it is important.
    Int J Tuberc Lung Dis. 2021;25:521-524.
    PubMed    


  358. SALZER HJF, Wang JY
    Chronic pulmonary aspergillosis as a sequel to pulmonary TB.
    Int J Tuberc Lung Dis. 2021;25:519-520.
    PubMed    


    June 2021
  359. AGOSTINIS A, Heffernan C, Long R, Beckon A, et al
    Interferon-gamma release assays for latent tuberculosis infection screening in Canadian federal correctional facilities.
    Int J Tuberc Lung Dis. 2021;25:447-452.
    PubMed     Abstract available


  360. TEO AKJ, Ong CWM, Hsu LY
    COVID-19 and TB: a progression-regression conundrum.
    Int J Tuberc Lung Dis. 2021;25:421-423.
    PubMed    


  361. BASHAM CA, Romanowski K, Johnston JC
    Alcohol use disorder and TB survivor health.
    Int J Tuberc Lung Dis. 2021;25:516-517.
    PubMed    


  362. MANTSHONYANE L, Kgwaadira B, Gross R
    The absence of evidence of cure is not a risk for recurrent TB among patients treated for TB.
    Int J Tuberc Lung Dis. 2021;25:511-512.
    PubMed    


  363. ROYCROFT E, Fitzgibbon MM, Kelly DM, Scully M, et al
    The largest prison outbreak of TB in Western Europe investigated using whole-genome sequencing.
    Int J Tuberc Lung Dis. 2021;25:491-497.
    PubMed     Abstract available


  364. SZKWARKO D, Amisi JA, Peterson D, Burudi S, et al
    Using a mobile application to improve pediatric presumptive TB identification in western Kenya.
    Int J Tuberc Lung Dis. 2021;25:468-474.
    PubMed     Abstract available


  365. REDWOOD L, Mitchell EMH, Viney K, Snow K, et al
    Depression, stigma and quality of life in people with drug-susceptible TB and drug-resistant TB in Vietnam.
    Int J Tuberc Lung Dis. 2021;25:461-467.
    PubMed     Abstract available


  366. OELOFSE S, Esmail A, Diacon AH, Conradie F, et al
    Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
    Int J Tuberc Lung Dis. 2021;25:453-460.
    PubMed     Abstract available


  367. CHAISSON LH, Naufal F, Delgado-Barroso P, Alvarez-Manzo HS, et al
    A systematic review of the number needed to screen for active TB among people living with HIV.
    Int J Tuberc Lung Dis. 2021;25:427-435.
    PubMed     Abstract available


  368. TAVOSCHI L, Toscanini F, Pontali E
    TB and prisons: confinement does not contain the disease.
    Int J Tuberc Lung Dis. 2021;25:424-426.
    PubMed    


  369. AKKERMAN OW, Tiberi S, Alffenaar JW
    Shortening MDR-TB treatment: is treating more patients with fewer drugs better?
    Int J Tuberc Lung Dis. 2021;25:419-420.
    PubMed    


    May 2021
  370. ZOKUFA N, Lebelo K, Hacking D, Tabo L, et al
    Community-based TB testing as an essential part of TB recovery plans in the COVID-19 era.
    Int J Tuberc Lung Dis. 2021;25:406-408.
    PubMed    


  371. POLLOCK NR, MacIntyre AT, Blauwkamp TA, Blair L, et al
    Detection of Mycobacterium tuberculosis cell-free DNA to diagnose TB in pediatric and adult patients.
    Int J Tuberc Lung Dis. 2021;25:403-405.
    PubMed    


  372. MIN J, Kang JY, Kim J, Yang J, et al
    Impact of COVID-19 on TB services in Korea.
    Int J Tuberc Lung Dis. 2021;25:400-402.
    PubMed    


  373. MARGINEANU I, Mor Z, Garcia D, Gilpin C, et al
    TB and COVID-19 in migrants - the need to focus on both conditions.
    Int J Tuberc Lung Dis. 2021;25:333-335.
    PubMed    


  374. MCQUAID CF, Foster N, Quaife M, Levy J, et al
    Digital adherence technology for TB: focus on livelihoods as well as lives.
    Int J Tuberc Lung Dis. 2021;25:416-417.
    PubMed    


  375. RICCARDI N, Saderi L, Borroni E, Tagliani E, et al
    Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study.
    Int J Tuberc Lung Dis. 2021;25:395-399.
    PubMed     Abstract available


  376. KALEMA N, Semeere A, Banturaki G, Kyamugabwa A, et al
    Gaps in TB preventive therapy for persons initiating antiretroviral therapy in Uganda: an explanatory sequential cascade analysis.
    Int J Tuberc Lung Dis. 2021;25:388-394.
    PubMed     Abstract available


  377. SATYANARAYANA S, Bhatia V, Mandal PP, Kanchar A, et al
    Urgent need to address the slow scale-up of TB preventive treatment in the WHO South-East Asia Region.
    Int J Tuberc Lung Dis. 2021;25:382-387.
    PubMed     Abstract available


  378. FERREIRO L, Ruano-Ravina A, Otero-Mallo R, Pou-Alvarez C, et al
    Recent epidemiological trends in extrapulmonary TB in Galicia, Spain.
    Int J Tuberc Lung Dis. 2021;25:373-381.
    PubMed     Abstract available


  379. WEYENGA H, Karanja M, Onyango E, Katana AK, et al
    Can isoniazid preventive therapy be scaled up rapidly? Lessons learned in Kenya, 2014-2018.
    Int J Tuberc Lung Dis. 2021;25:367-372.
    PubMed     Abstract available


  380. MARTSON AG, Kim HY, Marais B, Alffenaar JW, et al
    The importance of pharmacokinetics/pharmacodynamics assessment in Phase IIB/III trials for MDR-TB treatment.
    Int J Tuberc Lung Dis. 2021;25:336-339.
    PubMed    


    April 2021
  381. MALABAD JCM, Ang CF, Palabrica FAR, Cajucom MAM, et al
    Molecular epidemiology of Mycobacterium tuberculosis in adult Filipino TB-HIV co-infected patients.
    Int J Tuberc Lung Dis. 2021;25:285-291.
    PubMed     Abstract available


  382. HARRIES AD, Kumar AMV, Satyanarayana S, Thekkur P, et al
    TB and COVID-19: measuring key risk factors that affect treatment outcomes.
    Int J Tuberc Lung Dis. 2021;25:329-331.
    PubMed    


  383. COX V, Guglielmetti L, Hewison C, Reuter A, et al
    Reply to: "Human rights: finding the right balance for rifampicin-resistant TB treatment".
    Int J Tuberc Lung Dis. 2021;25:328-329.
    PubMed    


  384. VAN DEUN A, Piubello A, Lynen L, de Jong BC, et al
    Human rights: finding the right balance for rifampicin-resistant TB treatment.
    Int J Tuberc Lung Dis. 2021;25:327-328.
    PubMed    


  385. GULLON-BLANCO JA, Rodrigo-Sanz T, Alvarez-Navascues F, Tabernero-Huguet E, et al
    Completion of treatment for latent TB infection in a low prevalence setting.
    Int J Tuberc Lung Dis. 2021;25:321-323.
    PubMed    


  386. ROY N, Krishnamoorthy Y, Rajaa S, Ezhumalai K, et al
    Health-related quality of life and its effect on TB treatment outcomes.
    Int J Tuberc Lung Dis. 2021;25:318-320.
    PubMed    


  387. BHERING M, Duarte R, Kritski A
    Treatment outcomes and predictive factors for multidrug-resistant TB and HIV coinfection in Rio de Janeiro State, Brazil.
    Int J Tuberc Lung Dis. 2021;25:292-298.
    PubMed     Abstract available


  388. CHESOV D, Butov D, Reimann M, Heyckendorf J, et al
    Impact of lung function on treatment outcome in patients with TB.
    Int J Tuberc Lung Dis. 2021;25:277-284.
    PubMed     Abstract available


  389. VISCA D, D Ambrosio L, Centis R, Pontali E, et al
    Post-TB disease: a new topic for investigation-and why it matters.
    Int J Tuberc Lung Dis. 2021;25:258-261.
    PubMed    


  390. LAU A, Ferrara G
    Disseminated TB: still being missed and misunderstood.
    Int J Tuberc Lung Dis. 2021;25:255-257.
    PubMed    


  391. SCHULTINK MP, Kerstjens HAM, Ter Beek L, Zondag H, et al
    Assessment of TB treatment on patient well-being.
    Int J Tuberc Lung Dis. 2021;25:315-317.
    PubMed    


    March 2021
  392. KUMAR MS, Surendran D, Manu MS, Rakesh PS, et al
    Mortality due to TB-COVID-19 coinfection in India.
    Int J Tuberc Lung Dis. 2021;25:250-251.
    PubMed    


  393. GRACIAA DS, Kempker RR, Sanikidze E, Tukvadze S, et al
    TB research amidst the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2021;25:167-170.
    PubMed    


  394. ALLWOOD BW, van der Zalm MM, Mortimer K
    Reply to "Clinical care for patients with post TB lung disease".
    Int J Tuberc Lung Dis. 2021;25:253-254.
    PubMed    


  395. GUNTHER G, Ithete S
    Clinical care for patients with post-TB lung disease.
    Int J Tuberc Lung Dis. 2021;25:252-253.
    PubMed    


  396. PARK JH, Jung J, Kim JY, Hong MJ, et al
    Airborne precautions based on Xpert((R)) MTB/RIF results for patients with presumptive TB.
    Int J Tuberc Lung Dis. 2021;25:244-246.
    PubMed    


  397. KIZNY GORDON A, Tong SYC, Martinez E, Crighton T, et al
    TB genomic surveillance and data sharing in recognising contamination events.
    Int J Tuberc Lung Dis. 2021;25:241-243.
    PubMed    


  398. BAIK Y, Nalutaaya A, Kitonsa PJ, Dowdy DW, et al
    Infection status of contacts is not associated with severity of TB in the index case.
    Int J Tuberc Lung Dis. 2021;25:237-240.
    PubMed    


  399. ADANKWAH E, Arthur RA, Minadzi D, Owusu DO, et al
    Immune response against TB and non-tuberculous mycobacterial pulmonary disease.
    Int J Tuberc Lung Dis. 2021;25:234-236.
    PubMed    


  400. MALIK AA, Fuad J, Abbass W, Ikhlaque S, et al
    Preventive treatment of drug-resistant TB in a rural setting.
    Int J Tuberc Lung Dis. 2021;25:231-233.
    PubMed    


  401. CATES L, Crudu V, Codreanu A, Ciobanu N, et al
    Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting.
    Int J Tuberc Lung Dis. 2021;25:228-230.
    PubMed    


  402. COX SR, Gupte AN, Thomas B, Gaikwad S, et al
    Unhealthy alcohol use independently associated with unfavorable TB treatment outcomes among Indian men.
    Int J Tuberc Lung Dis. 2021;25:182-190.
    PubMed     Abstract available


  403. SOHN H, Sweeney S, Mudzengi D, Creswell J, et al
    Determining the value of TB active case-finding: current evidence and methodological considerations.
    Int J Tuberc Lung Dis. 2021;25:171-181.
    PubMed     Abstract available


    February 2021
  404. BARRETT J, Painter H, Rajgopal A, Keane D, et al
    Increase in disseminated TB during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2021;25:160-166.
    PubMed    


  405. ALLWOOD BW, van der Zalm MM, Mortimer K
    Reply to: Taking action to improve post-TB lung health.
    Int J Tuberc Lung Dis. 2021;25:163a-163.
    PubMed    


  406. HARRIES AD, Dlodlo RA, Brigden G, Chakaya JM, et al
    Taking action to improve post-TB lung health.
    Int J Tuberc Lung Dis. 2021;25:161-162.
    PubMed    


  407. MOLINA-MOYA B, Guglielmetti L, Bothamley G, van Leth F, et al
    Use and impact of molecular methods for detecting drug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:157-159.
    PubMed    


  408. LAW WS, Chan CKA, Leung CC
    Management of latent TB infection in child household contacts aged under 5 years.
    Int J Tuberc Lung Dis. 2021;25:151-153.
    PubMed    


  409. MEHTA SN, Murrill M, Suryavanshi N, Bhosale R, et al
    TB-related knowledge and stigma among pregnant women in low-resource settings.
    Int J Tuberc Lung Dis. 2021;25:148-150.
    PubMed    


  410. ARSCOTT-MILLS T, Ejelonu A, Mokalane K, Machao G, et al
    One third of child TB cases were missing from the national TB register in Botswana.
    Int J Tuberc Lung Dis. 2021;25:142-144.
    PubMed    


  411. DE VOS E, Scott L, Voss De Lima Y, Warren RM, et al
    Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa.
    Int J Tuberc Lung Dis. 2021;25:134-141.
    PubMed     Abstract available


  412. SOTGIU G, Rosales-Klintz S, Centis R, D'Ambrosio L, et al
    TB management in the European Union/European Economic Area: a multi-centre survey.
    Int J Tuberc Lung Dis. 2021;25:126-133.
    PubMed     Abstract available


  413. FOX GJ, Johnston JC, Nguyen TA, Majumdar SS, et al
    Active case-finding in contacts of people with TB.
    Int J Tuberc Lung Dis. 2021;25:95-105.
    PubMed     Abstract available


  414. LINH NN, Miller C, Marks GB
    Potential benefits of active case finding to reduce the burden of TB.
    Int J Tuberc Lung Dis. 2021;25:93-94.
    PubMed    


    January 2021
  415. SHEN X, Sha W, Yang C, Pan Q, et al
    Continuity of TB services during the COVID-19 pandemic in China.
    Int J Tuberc Lung Dis. 2021;25:81-83.
    PubMed    



  416. TB and COVID-19 co-infection: rationale and aims of a global study.
    Int J Tuberc Lung Dis. 2021;25:78-80.
    PubMed    


  417. MAUG AKJ, Hossain MA, Gumusboga M, Decroo T, et al
    Finding the right balance between efficacy and tolerability for TB treatment: the search continues.
    Int J Tuberc Lung Dis. 2021;25:84-86.
    PubMed    


  418. PARIGI S, Venturini E, Galli L, Chiappini E, et al
    Xpert((R)) MTB/RIF Ultra performance in diagnosing paediatric pulmonary TB in gastric aspirates.
    Int J Tuberc Lung Dis. 2021;25:75-77.
    PubMed    


  419. SAKR CJ, Musharrafieh UM, Banna HS, Hoteit RA, et al
    Risks and benefits of QuantiFERON((R))-TB testing for LTBI screening of health workers.
    Int J Tuberc Lung Dis. 2021;25:72-74.
    PubMed    


  420. GENDERINI FG, Dauby N, Delforge M, De Wit S, et al
    TB in the intensive care unit in a low-endemic country.
    Int J Tuberc Lung Dis. 2021;25:69-71.
    PubMed    


  421. NABISERE R, Arinaitwe A, Muyise R, Asienzo J, et al
    Implementation of TB preventive therapy in Uganda: effect of an intervention on completion rates.
    Int J Tuberc Lung Dis. 2021;25:64-65.
    PubMed    


  422. TUCKER A, Oyuku D, Nalugwa T, Nantale M, et al
    Costs along the TB diagnostic pathway in Uganda.
    Int J Tuberc Lung Dis. 2021;25:61-63.
    PubMed    


  423. MAVE V, Kadam D, Gaikwad S, Kinikar A, et al
    Measuring TB drug levels in the hair in adults and children to monitor drug exposure and outcomes.
    Int J Tuberc Lung Dis. 2021;25:52-60.
    PubMed     Abstract available


  424. MESFIN AB, Araia ZZ, Beyene HN, Mebrahtu AH, et al
    First molecular-based anti-TB drug resistance survey in Eritrea.
    Int J Tuberc Lung Dis. 2021;25:43-51.
    PubMed     Abstract available


  425. SENEADZA NAH, Antwi S, Yang H, Enimil A, et al
    Effect of malnutrition on the pharmacokinetics of anti-TB drugs in Ghanaian children.
    Int J Tuberc Lung Dis. 2021;25:36-42.
    PubMed     Abstract available


  426. WROHAN I, Redwood L, Ho J, Velen K, et al
    Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
    Int J Tuberc Lung Dis. 2021;25:23-30.
    PubMed     Abstract available


  427. SOH AZ, Tan CTY, Mok E, Chee CBE, et al
    Adipokines and the risk of active TB: a nested case-control study.
    Int J Tuberc Lung Dis. 2021;25:31-35.
    PubMed     Abstract available


    December 2020
  428. ZHANG H, Cao X, Wang D, Xin H, et al
    The acquisition of Mycobacterium tuberculosis infection in village doctors in China: a prospective study.
    Int J Tuberc Lung Dis. 2020;24:1241-1246.
    PubMed     Abstract available


  429. FANG JL, Chao CM, Tang HJ
    The impact of COVID-19 on the diagnosis of TB in Taiwan.
    Int J Tuberc Lung Dis. 2020;24:1321-1322.
    PubMed    


  430. SINGH J, Ehtesham NZ, Hasnain SE
    Two parallel pandemics: the challenges faced by countries with COVID-19 and TB.
    Int J Tuberc Lung Dis. 2020;24:1319-1320.
    PubMed    


    November 2020
  431. FATIMA R, Yaqoob A
    In Reply: How TB and COVID-19 compare: an opportunity to integrate both control programmes.
    Int J Tuberc Lung Dis. 2020;24:1227-1228.
    PubMed    


  432. DE SOUZA CDF, Coutinho HS, Costa MM, Magalhaes MAFM, et al
    Impact of COVID-19 on TB diagnosis in Northeastern Brazil.
    Int J Tuberc Lung Dis. 2020;24:1220-1222.
    PubMed    


  433. ZHOU S, Van Staden Q, Toska E
    Resource reprioritisation amid competing health risks for TB and COVID-19.
    Int J Tuberc Lung Dis. 2020;24:1215-1216.
    PubMed    


  434. KADOTA JL, Reza TF, Nalugwa T, Kityamuwesi A, et al
    Impact of shelter-in-place on TB case notifications and mortality during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2020;24:1212-1214.
    PubMed    


  435. HAAS MK, Ignatius EH, Stout JE, Dooley KE, et al
    Finding the right balance between efficacy and tolerability for TB treatment.
    Int J Tuberc Lung Dis. 2020;24:1225b-1226.
    PubMed    


  436. WANG EY, Ahluwalia IB, Mase SR
    Response to Correspondence: The impact of smoking on TB treatment outcomes includes recurrent TB.
    Int J Tuberc Lung Dis. 2020;24:1225a-1225.
    PubMed    


  437. DHAMGAYE TM
    In reply: Latent TB treatment in pregnant women: a patient perspective.
    Int J Tuberc Lung Dis. 2020;24:1226-1227.
    PubMed    


  438. CHIANG CY, Bam TS
    The impact of smoking on TB treatment outcomes includes recurrent TB.
    Int J Tuberc Lung Dis. 2020;24:1224-1225.
    PubMed    


    October 2020
  439. KIM HW, Min J, Shin AY, Koo HK, et al
    Reasons why patients with tuberculosis in South Korea stop anti-TB treatment: a cross-sectional study.
    Int J Tuberc Lung Dis. 2020;24:1016-1023.
    PubMed     Abstract available


  440. SHAHRIARIRAD R, Fallahi MJ
    TB and the COVID-19 pandemic: brothers in arms against lung health.
    Int J Tuberc Lung Dis. 2020;24:1126-1127.
    PubMed    


  441. WU Z, Chen J, Xia Z, Pan Q, et al
    Impact of the COVID-19 pandemic on the detection of TB in Shanghai, China.
    Int J Tuberc Lung Dis. 2020;24:1122-1124.
    PubMed    


  442. MENEGUIM AC, Rebello L, Das M, Ravi S, et al
    Adapting TB services during the COVID-19 pandemic in Mumbai, India.
    Int J Tuberc Lung Dis. 2020;24:1119-1121.
    PubMed    


  443. HELDAL E, Dlodlo RA
    Estimating subnational TB burden-why not strengthen and use routine recording and reporting?
    Int J Tuberc Lung Dis. 2020;24:1125-1127.
    PubMed    


  444. AKKERMAN OW, Tiberi S
    The importance of knowing why TB patients stop anti-TB treatment.
    Int J Tuberc Lung Dis. 2020;24:989-990.
    PubMed    


    September 2020
  445. YASSIN M, Grzemska M
    Response to 'The Green Light Committee could contribute to ending tuberculosis .
    Int J Tuberc Lung Dis. 2020;24:984.
    PubMed    


  446. NGUYEN TBP, Nguyen TA, Luu BK, Le TTO, et al
    A comparison of digital chest radiography and Xpert((R)) MTB/RIF in active case finding for tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:934-940.
    PubMed     Abstract available


  447. CHIANG CH, Lee GH, Chiang TH, Tang PU, et al
    Disseminated Mycobacterium avium complex infection as a differential diagnosis of tuberculosis in HIV patients.
    Int J Tuberc Lung Dis. 2020;24:922-927.
    PubMed     Abstract available


  448. LOVEDAY M, Hlangu S, Furin J
    Breastfeeding in women living with tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:880-891.
    PubMed     Abstract available


  449. ADEWOLE OO
    Impact of COVID-19 on TB care: experiences of a treatment centre in Nigeria.
    Int J Tuberc Lung Dis. 2020;24:981-982.
    PubMed    


  450. VAN DER WALT M, Keddy KH
    How COVID-19 can instruct TB research: ensuring the safety of researchers exposed to infectious disease.
    Int J Tuberc Lung Dis. 2020;24:978-980.
    PubMed    


  451. WILSON FA, Miller TL, Stimpson JP
    COVID-19 and TB control in immigrant communities.
    Int J Tuberc Lung Dis. 2020;24:975-977.
    PubMed    


  452. ECHEVERRIA G, Espinoza W, de Waard JH
    How TB and COVID-19 compare: an opportunity to integrate both control programmes.
    Int J Tuberc Lung Dis. 2020;24:971-974.
    PubMed    


  453. MULDER C, Nkiligi E, Kondo Z, Scholten JN, et al
    What to look for when using SUBsET for subnational TB incidence estimates.
    Int J Tuberc Lung Dis. 2020;24:983-984.
    PubMed    


  454. WANG J, Garcia-Basteiro AL
    Should vitamin D supplementation be used concomitantly with LTBI treatment?
    Int J Tuberc Lung Dis. 2020;24:875-876.
    PubMed    


    August 2020
  455. CHIANG CY
    Green Light Committee and WHO recommendations.
    Int J Tuberc Lung Dis. 2020;24:873-874.
    PubMed    


    June 2020
  456. HARRIES AD
    In Response to Reinout van Crevel et al.
    Int J Tuberc Lung Dis. 2020;24:634.
    PubMed    


    May 2020
  457. FURIN J
    Can Green Light Committees help "end TB"?
    Int J Tuberc Lung Dis. 2020;24:540.
    PubMed    


    April 2020
  458. BASHAM CA, Romanowski K, Johnston JC
    Cardiovascular disease: the forgotten cousin of post-TB health?
    Int J Tuberc Lung Dis. 2020;24:466-467.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.